Abstract
The assertion that primary headaches are a social disease is now out of the question, being established both by a high prevalence rate and by the impact they produce on the person and society. The negative loop of these premises is overturned on the vertical economic damage they cause, another solid evidence in the scientific literature. This expansion from personal to social damage, in terms of current expenditure of the national health systems, requires as a natural consequence a more efficient organization of the health services dedicated to control, education, rehabilitation, to achieve social care equity. Migraine represents the perfect paradigm of this path.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hung PH, Fuh JL, Wang SJ. Validity, reliability and application of the Taiwan version of the migraine disability assessment questionnaire. J Formos Med Assoc. 2006;105(7):563–8.
Wang SJ, Wang PJ, Fuh JL, Peng KP, Ng K. Comparisons of disability, quality of life, and resource use between chronic and episodic migraineurs: a clinic-based study in Taiwan. Cephalalgia. 2013;33(3):171–81.
Iigaya M, Sakai F, Kolodner KB, Lipton RB, Stewart WF. Reliability and validity of the Japanese Migraine Disability Assessment (MIDAS) Questionnaire. Headache. 2003;43(4):343–52.
Yu S, Liu R, Zhao G, Yang X, Qiao X, Feng J, et al. The prevalence and burden of primary headaches in China: a population-based door-to-door survey. Headache. 2012;52(4):582–91.
Fuh JL, Wang SJ, Lu SR. Impact of migraine on the employed labor force in Taiwan. J Chin Med Assoc. 2008;71(2):74–8.
Tang CH, Chen YC, Ng K, Wang SJ. A retrospective matched case-control study on medical costs of refractory migraine in Taiwan. Headache. 2013;53(3):526–39.
Roh JK, Kim JS, Ahn YO. Epidemiologic and clinical characteristics of migraine and tension-type headache in Korea. Headache. 1998;38(5):356–65.
GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018;17(11):954–976.
Peng KP, Wang SJ. Epidemiology of headache disorders in the Asia-Pacific region. Headache. 2014;54(4):610–8.
Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31(3):301–15.
Vo P, Fang J, Bilitou A, Laflamme AK, Gupta S. Patients' perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom. J Headache Pain. 2018;19(1):82.
GBD 2019 Demographics Collaborators. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1160–203. https://doi.org/10.1016/S0140-6736(20)30977-6.
Linde M, Gustavsson A, Stovner LJ, et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 2012;19(5):703–11. https://doi.org/10.1111/j.1468-1331.2011.03612.x.
Irimia P, Garrido-Cumbrera M, Santos-Lasaosa S, et al. Estimating the savings associated with a migraine-free life: results from the Spanish Atlas. Eur J Neurol. 2020;27(12):2616–24. https://doi.org/10.1111/ene.14431.
Messali A, Sanderson JC, Blumenfeld AM, Goadsby PJ, Buse DC, Varon SF, et al. Direct and indirect costs of chronic and episodic migraine in the United States: a web-based survey. Headache. 2016;56(2):306–22.
Vicente-Herrero T, Burke TA, Laínez MJA. The impact of a worksite migraine intervention program on work productivity, productivity costs, and non-workplace impairment among Spanish postal service employees from an employer perspective. Curr Med Res Opin. 2004;20(11):1805–14. https://doi.org/10.1185/030079904X10151.
Schaetz L, Rimner T, Pathak P, et al. Employee and employer benefits from a migraine management program: disease outcomes and cost analysis. Headache. 2020;60(9):1947–60. https://doi.org/10.1111/head.13933.
Haw NJ, Cabaluna IT, Kaw GE, Cortez JF, Chua MP, Guce K. A cross-sectional study on the burden and impact of migraine on work productivity and quality of life in selected workplaces in the Philippines. J Headache Pain. 2020;21(1):125. https://doi.org/10.1186/s10194-020-01191-6.
Wong LP, Alias H, Bhoo-Pathy N, et al. Impact of migraine on workplace productivity and monetary loss: a study of employees in banking sector in Malaysia. J Headache Pain. 2020;21(1):68. https://doi.org/10.1186/s10194-020-01144-z.
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. https://doi.org/10.1177/0333102417738202.
Yang M, Rendas-Baum R, Varon SF, Kosinski M. Validation of the headache impact test (HIT-6TM) across episodic and chronic migraine. Cephalalgia. 2011;31(3):357–67. https://doi.org/10.1177/0333102410379890.
Prasad M, Wahlqvist P, Shikiar R, Shih YCT. A review of self-report instruments measuring health-related work productivity: a patient-reported outcomes perspective. PharmacoEconomics. 2004;22(4):225–44. https://doi.org/10.2165/00019053-200422040-00002.
Grupo de Trabajo Multidisciplinar del Atlas de la Migraña en España (2018) Impacto y Situación de La Migraña En España: Atlas 2018. Editorial Universidad de Sevilla 1–183. ISBN:978-84-472-2832-4.
Marcus SC, Shewale AR, Silberstein SD, et al. Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response. Cephalalgia. 2020;40(7):639–49. https://doi.org/10.1177/0333102420915167.
World Health Organization. Workers’ health: global plan of action. https://www.who.int/occupational_health/publications/global_plan/en/. Accessed 13 Dec 2020.
Chandana SR, Movva S, Arora M, et al. Primary brain tumors in adults. Am Fam Physician. 2008;77:1423–30.
Goffaux P, Fortin D. Brain tumor headaches: from bedside to bench. Neurosurgery. 2010;67:459–66.
Purdy RA, Kirby S. Headaches and brain tumors. Neurol Clin. 2004;22:39–53.
Pfund Z, Szapary L, Jaszberenyi O, et al. Headache in intracranial tumors. Cephalalgia. 1999;19:787–90.
Index Mundi. Ethiopia age structure 2019. https://www.indexmundi.com/ethiopia/age_structure.html (accessed 4 April 2020).
Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basáñez MG, Baxter A, Bell ML, Benjamin EJ, Bennett D, Bernabé E, Bhalla K, Bhandari B, Bikbov B, Bin Abdulhak A, et al. Years lived with disability (YLD) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2163–96.
Vos T, Barber RM, Bell B, Bertozzi-Villa A, Biryukov S, Bolliger I, Charlson F, Davis A, Degenhardt L, Dicker D, Duan L, Erskine H, Feigin VL, Ferrari AJ, Fitzmaurice C, Fleming T, Graetz N, Guinovart C, Haagsma J, Hansen GM, Hanson SW, Heuton KR, Higashi H, Kassebaum N, Kyu H, Laurie E, Liang X, Lofgren K, Lozano R, MacIntyre MF, Moradi-Lakeh M, Naghavi M, Nguyen G, Odell S, Ortblad K, Roberts DA, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2015;386:743–800.
GBD (2015) Disease and injury incidence and prevalence collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388:1545–602.
GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–59.
GBD (2017) Disease and injury incidence and prevalence collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2017;392:1789–858.
Steiner TJ. Lifting the burden: the global campaign against headache. Lancet Neurol. 2004;3:204–5.
Steiner TJ. Lifting The Burden: the global campaign to reduce the burden of headache worldwide. J Headache Pain. 2005;6:373–7.
Steiner TJ, Birbeck GL, Jensen R, Katsarava Z, Martelletti P, Stovner LJ. The global campaign, World Health Organization and Lifting The Burden: collaboration in action. J Headache Pain. 2011;12:273–4.
Lifting The Burden. http://www.l-t-b.org (Accessed 4 Apr 2020).
Wöber C, Wöber-Bingöl C, Uluduz D, Aslan TS, Uygunoglu U, Tüfekçi A, Alp SI, Duman T, Sürgün F, Emir GK, Demir CF, Balgetir F, Özdemir YB, Auer T, Siva A, Steiner TJ. Undifferentiated headache: broadening the approach to headache in children and adolescents, with supporting evidence from a nationwide school-based cross-sectional survey in Turkey. J Headache Pain. 2018;19:18.
Philipp J, Zeiler M, Wöber C, Wagner G, Karwautz AFK, Steiner TJ, Wöber-Bingöl C. Prevalence and burden of headache in children and adolescents in Austria—a nationwide study in a representative sample of pupils aged 10-18 years. J Headache Pain. 2019;20:101.
Zebenigus M, Tekle-Haimanot R, Worku DK, Thomas H, Steiner TJ. The prevalence of primary headache disorders in Ethiopia. J Headache Pain. 2016;17:110.
Wöber-Bingöl C, Wöber C, Uluduz D, Uygunoğlu U, Aslan T, Kernmayer M, Zesch H-E, Gerges NTA, Wagner G, Siva A, Steiner TJ. The global burden of headache in children and adolescents—developing a questionnaire and methodology for a global study. J Headache Pain. 2014;15:86.
Genc D, Vaičienė-Magistris N, Zaborskis A, Şaşmaz T, Tunç AY, Uluduz D, Steiner TJ. The prevalence of headache disorders in children and adolescents in Lithuania: a schools-based study. J Headache Pain. 2020;21:73.
Zewde YZ, Zebenigus M, Demissie H, Tekle-Haimanot R, Uluduz D, Şaşmaz T, Bozdag F, Steiner TJ. The prevalence of headache disorders in children and adolescents in Ethiopia: a schools-based study. J Headache Pain. 2020;21(1):108.
Saylor D, Steiner TJ. The global burden of headache. Semin Neurol. 2018;38:182–90.
Steiner TJ, Stovner LJ, Vos T, Jensen R, Katsarava Z. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19:17.
Lifting The Burden. http://www.l-t-b.org (Accessed 19 June 2019).
Steiner TJ, Birbeck GL, Jensen R, Katsarava Z, Martelletti P, Stovner LJ. Lifting The Burden: the first 7 years. J Headache Pain. 2010;11:451–5.
Steiner TJ, Gururaj G, Andrée C, Katsarava Z, Ayzenberg I, Yu S-Y, Al Jumah M, Tekle-Haimanot R, Birbeck GL, Herekar A, Linde M, Mbewe E, Manandhar K, Risal A, Jensen R, Queiroz L-P, Scher AI, Wang S-J, Stovner TJ. Diagnosis, prevalence estimation and burden measurement in population surveys of headache: presenting the HARDSHIP questionnaire. J Headache Pain. 2014;15:3.
Stovner LJ, Al Jumah M, Birbeck GL, Gururaj G, Jensen R, Katsarava Z, Queiroz L-P, Scher AI, Tekle-Haimanot R, Wang S-J, Steiner TJ. The methodology of population surveys of headache prevalence, burden and cost: principles and recommendations. A product of the Global Campaign against Headache. J Headache Pain. 2014;15:5.
Manandhar K, Risal A, Steiner TJ, Holen A, Linde M. The prevalence of primary headache disorders in Nepal: a nationwide population-based study. J Headache Pain. 2015;16:95.
Linde M, Edvinsson L, Manandhar K, Risal A, Steiner TJ. Migraine associated with altitude: results from a population-based study in Nepal. Eur J Neurol. 2017;24:1055–61.
Wang Y, Xie J, Yang F, et al. The prevalence of primary headache disorders and their associated factors among nursing staff in North China. J Headache Pain. 2015;16:4.
Yu SY, Cao XT, Zhao G, et al. The burden of headache in China: validation of diagnostic questionnaire for a population-based survey. J Headache Pain. 2011;12(2):141–6.
Minen MT, De Dhaem OB, Van Diest AK, Powers S, Schwedt TJ, Lipton R, et al. Migraine and its psychiatric comorbidities. J Neurol Neurosurg Psychiatry. 2016;87(7):741–9.
Teixeira AL, Costa EAC, da Silva AA, dos Santos IAM, Gómez RS, Kummer A, et al. Psychiatric comorbidities of chronic migraine in community and tertiary care clinic samples. J Headache Pain. 2012;13(7):551.
Subramaniam M, Vaingankar JA, Abdin E, Chong SA. Psychiatric morbidity in pain conditions: results from the Singapore Mental Health Study. Pain Res Manag. 2013;18(4):185–90.
Singapore Department of Statistics. Population trends 2014 2014. Retrieved from https://www.singstat.gov.sg/modules/infographics/population
McWilliams LA, Goodwin RD, Cox BJ. Depression and anxiety associated with three pain conditions: results from a nationally representative sample. Pain. 2004;111(1–2):77–83.
Risal A, Manandhar K, Holen A, Steiner TJ, Linde M. Comorbidities of psychiatric and headache disorders in Nepal: implications from a nationwide population-based study. J Headache Pain. 2016;17(1):45.
Buse DC, Loder EW, Gorman JA, Stewart WF, Reed ML, Fanning KM, et al. Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: results of the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2013;53(8):1278–99.
Tai M-LS, Yap JF, Goh CB. Dietary trigger factors of migraine and tension-type headache in a south east Asian country. J Pain Res. 2018;11:1255.
Zhang Y, Shi Z, Hock D, Yue W, Liu S, Zhang Y, et al. Prevalence of primary headache disorders in a population aged 60 years and older in a rural area of Northern China. J Headache Pain. 2016;17(1):83.
Camarda R, Monastero R. Prevalence of primary headaches in Italian elderly: preliminary data from the Zabut Aging Project. Neurol Sci. 2003;24(2):s122–4.
Victor T, Hu X, Campbell J, Buse D, Lipton R. Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia. 2010;30(9):1065–72.
Takeshima T, Ishizaki K, Fukuhara Y, Ijiri T, Kusumi M, Wakutani Y, et al. Population-based door-to-door survey of migraine in Japan: the Daisen study. Headache. 2004;44(1):8–19.
Bruti G, Magnotti M, Iannetti G. Migraine and depression: bidirectional co-morbidities? Neurol Sci. 2012;33(1):107–9.
Sivaji M, Manickavasagam J, Sundaramurthi I, Gopinathan S. A study on prevalence and co-morbidity of bipolar and anxiety disorders in chronic headache patients. Int J Res Med Sci. 2017;5(7):3038–43.
Jette N, Patten S, Williams J, Becker W, Wiebe S. Comorbidity of migraine and psychiatric disorders—a national population-based study. Headache. 2008;48(4):501–16.
Harnod T, Lin C-L, Kao C-H. Survival outcome and mortality rate in patients with migraine: a population-based cohort study. J Headache. 2018;19(1):57.
Sheffield RE. Migraine prevalence: a literature review. Headache. 1998;38:595–601.
Saed MG, Aly SM, Karim A Masood, editors. Red Sea Governorate achievement index. 2012. [Arabic].
Headache Classification Committee. The international classification of headache disorders (2nd edition). Cephalalgia. 2004;24:1–160.
Fernandes PT, Salgado PC, Naronha AL, de Boer HM, Prilipko L, Sander JW, Li LM. Epilepsy stigma perception in an urban area of a limited-resource country. Epilepsy Behav. 2007;11:25–32.
Nachit-Ouinekh F, Chrysostome V, Henry P, Sourgen C, Dartiques JE, El hasanoui A. Variability of reported headache symptoms and diagnosis of migraine at 12 months. Cephalalgia. 2005;25:117–23.
World Health Organization, Headache disorders. Fact sheet N_277, 2004.
Lipton R, Bigal M. Migraine: epidemiology, impact, and risk factors for progression. Headache J Head Face Pain. 2005;45:s1.
Tepper SJ, Dahlof C, Dowson A, Newman L, Mansbach H, Jones M, Pham B, Webster C, Salonen R. Prevalence and diagnosis of migraine in patients consulting their primary care physician with a complaint of headache: data from the landmark study. Headache. 2004;44:856–64.
Headache Classification Committee of the International Headache S. The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629–808.
Diamond M, Freitag F, Lipton R, Michael L, Reed L. Migraine prevention patterns in a community sample: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache The Journal of Head and Face Pain. 2005;45. Confrence: 47th Annual Scientific Meeting of the theAmerican Headache Society.
Kandil M, Hamed S, Fadel K, Khalifa H, Ghanem M, Mohamed K. Migraine in Assiut governorate, Egypt: epidemiology, risk factors, comorbid conditions and predictors of change from episodic to chronic migraine. Neurol Res. 2016;38(3):232–41.
Ghorbani A, Abtahi S, Fereidan-Esfahani M, Abtahi S, Shemshaki H, Akbari M, et al. Prevalence and clinical characteristics of headache among medical students, Isfahan. Iran J Res Med Sci. 2013;18(Suppl 1):S24–7.
Davies PTG, Peatfield RC, Steiner TJ, Bond RA, Rose FC. Some clinical comparisons between common and classical migraine: a questionnaire-based study. Cephalalgia. 1991;11:223–7.
Ranson R, Igarashi H, MacGregor EA, Wilkinson M. The similarities and differences of migraine with aura and migraine without aura: a preliminary study. Cephalalgia. 1991;11:189–92.
Zielger DK, Hassanein RS. Specific headache phenomena: their frequency and coincidence. Headache. 1990;30:152–6.
Ibrahim N, Alotaibi A, Alhazmi A, Alshehri R, Saimaldaher R, Murad M. Prevalence, predictors and triggers of migraine headache among medical students and interns in king Abdulaziz University, Jeddah, Saudi Arabia. Pak J Med Sci. 2017;33(2):270–5.
Noor T, Sajjad A, Asma A. Frequency, character and predisposing factor of headache among students of medical college of Karachi. J Pak Med Assoc. 2016;66(2):159–64.
Stovner LJ, Hagen K, Jensen R, Katsarava Z, Lipton RB, Scher AI, Steiner TJ, Zwart J-A. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27:193–210.
World Health Organization and Lifting The Burden. Atlas of headache disorders and resources in the world 2011. Geneva: WHO Press; 2011.
Steiner TJ, Birbeck GL, Jensen RH, Katsarava Z, Stovner LJ, Martelletti P. Headache disorders are third cause of disability worldwide. J Headache Pain. 2015;16:58.
United Nations Department of Economic and Social Affairs, Population Division. World population prospects: the 2015 revision. Key findings and advance tables (Working Paper No ESA/P/WP241). United Nations, New York 2015.
Kulkarni GB, Rao GN, Gururaj G, Stovner LJ, Steiner TJ. Headache disorders and public ill-health in India: prevalence estimates in Karnataka state. J Headache Pain. 2015;16:67.
Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, Carter A, Casey DC, Charlson FJ, Chen AZ, Coggeshall M, Cornaby L, Dandona L, Dicker DJ, Dilegge T, Erskine HE, Ferrari AJ, Fitzmaurice C, Fleming T, Forouzanfar MH, Fullman N, Gething PW, Goldberg EM, Graetz N, Haagsma JA, Hay SI, Johnson CO, Kassebaum NJ, Kawashima T, Kemmer L, Khalil IA, Kinfu Y, Kyu HH, Leung J, Liang X, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388:1545–602.
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789–858.
Lifting The Burden. http://www.l-t-b.org (Last accessed 29 Oct 2019).
Katsarava Z, Dzagnidze A, Kukava M, Mirvelashvili E, Djibuti M, Janelidze M, Jensen R, Stovner LJ, Steiner TJ. Primary headache disorders in the republic of Georgia: prevalence and risk factors. Neurology. 2009;73:1796–803.
Ayzenberg I, Katsarava Z, Sborowski A, Chernysh M, Osipova V, Tabeeva G, Yakhno N, Steiner TJ. The prevalence of primary headache disorders in Russia: a countrywide survey. Cephalalgia. 2012;32:373–81.
Mbewe E, Zairemthiama P, Yeh H-H, Paul R, Birbeck GL, Steiner TJ. The epidemiology of primary headache disorders in Zambia: a population-based door-to-door survey. J Headache Pain. 2015;16:30.
Herekar AA, Ahmad A, Uqaili UL, Ahmed B, Effendi J, Alvi SZ, Shahab MA, Javed U, Herekar AD, Khanani R, Steiner TJ. Primary headache disorders in the adult general population of Pakistan—a cross sectional nationwide prevalence survey. J Headache Pain. 2017;18:28.
Kingdom of Saudi Arabia General Authority for Statistics. The general population and housing census 2010. https://www.stats.gov.sa/en/13 (Last accessed 29 Oct 2019).
Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24(suppl 1):9–160.
Streel S, Donneau AF, Hoge A, Albert A, Schoenen J, Guillaume M. One-year prevalence of migraine using a validated extended French version of the ID migraine™: a Belgian population-based study. Rev Neurol (Paris). 2015;171:707–14.
Stovner LJ, Zwart JA, Hagen K, Terwindt GM, Pascual J. Epidemiology of headache in Europe. Eur J Neurol. 2006;13:333–45.
Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American migraine study II. Headache. 2001;41:646–57.
Leonardi M. Burden of migraine: what should we say more? Neurol Sci. 2015;36(Suppl 1):1–3.
Granella F, Cavallini A, Sandrini G, Manzoni GC, Nappi G. Long-term outcome of migraine. Cephalalgia. 1998;18:30–3.
Colombo B, Dalla Libera D, Dalla Costa G, Comi G. Refractory migraine: the role of the physician in assessment and treatment of a problematic disease. Neurol Sci. 2013;34(Suppl 1):109–12.
Vicente-Herrero MT, Iñiguez R, de la Torre MV, Capdevila García LM, López-González ÁA, Terradillos García MJ. Migraña crónica y trabajo. Riesgos laborales y aspectos preventivos. SEMERGEN - Med Familia. 2013;39(6):316–24. https://doi.org/10.1016/j.semerg.2012.10.006.
Mäki K, Vahtera J, Virtanen M, Elovainio M, Keltikangas-Järvinen L, Kivimäki M. Work Stress and New-Onset Migraine in a Female Employee Population. Cephalalgia. 2008;28(1):18–25. https://doi.org/10.1111/j.1468-2982.2007.01462.x.
Le H, Tfelt-Hansen P, Skytthe A, Kyvik KO, Olesen J. Association between migraine, lifestyle and socioeconomic factors: a population-based cross-sectional study. J Headache Pain. 2011;12(2):157–72. https://doi.org/10.1007/s10194-011-0321-9.
Etminan M, Brophy JM, Collins G, Nazemipour M, Mansournia MA. To adjust or not to adjust: the role of different covariates in cardiovascular observational studies. Am Heart J. 2021;237:62–7. https://doi.org/10.1016/j.ahj.2021.03.008.
Sjösten N, et al. Influence of retirement and work stress on headache prevalence: A longitudinal modelling study from the GAZEL Cohort Study. Cephalalgia. 2011;31(6):696–705. https://doi.org/10.1177/0333102410394677.
GBD (2019) Diseases and injuries collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396:1204–22.
Colas R, Munoz P, Temprano R, Gomez C, Pascual J. Chronic daily headache with analgesic over-use: epidemiology and impact on quality of life. Neurology. 2004;62:1338–42.
Katsarava Z, Muessig M, Dzagnidze A, Fritsche G, Diener HC, Limmroth V. Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia. 2005;25:12–5.
Jonsson P, Hedenrud T, Linde M. Epidemiology of medication overuse headache in the general Swedish population. Cephalalgia. 2011;31:1015–22.
Lampl C, Thomas H, Stovner LJ, Tassorelli C, Katsarava Z, Laínez JMA, Lantéri-Minet M, Rastenyte D, Ruiz de la Torre E, Andrée C, Steiner TJ. Interictal burden attributable to episodic headache: findings from the Eurolight project. J Headache Pain. 2016;17:9.
Straube A, et al. Headache in school children: prevalence and risk factors. Dtsch Arztebl Int. 2013;110(48):811–8.
Xavier MK, et al. Prevalence of headache in adolescents and association with use of computer and videogames. Cien Saude Colet. 2015;20(11):3477–86.
Li C, et al. Prevalence of primary headache disorders among information technology staff in China: the negative effects of computer use and other correlative factors. BMC Public Health. 2020;20(1):443.
Wang J, et al. Mobile phone use and the risk of headache: a systematic review and meta-analysis of cross-sectional studies. Sci Rep. 2017;7(1):12595.
Altamura C, et al. Locking down the CGRP pathway during the COVID-19 pandemic lockdown: the PandeMig study. Neurol Sci. 2020;41(12):3385–9.
Porta-Etessam J, et al. Spectrum of headaches associated with SARS-CoV-2 infection: study of healthcare professionals. Headache. 2020;60:1697–704.
Al-Hashel JY, et al. Impact of coronavirus disease 2019 (COVID-19) pandemic on patients with migraine: a web-based survey study. J Headache Pain. 2020;21(1):115.
Smith AP. Acute tension-type headaches are associated with impaired cognitive function and more negative mood. Front Neurol. 2016;7:42.
Moore DJ, et al. Headache impairs attentional performance. Pain. 2013;154(9):1840–5.
Monzani L, et al. Anxiety and the severity of tension-type headache mediate the relation between headache presenteeism and workers' productivity. PLoS One. 2018;13(7):e0201189.
Andrée C, et al. Headache yesterday in Europe. J Headache Pain. 2014;15(1):33.
Suzuki N, Ishikawa Y, Gomi S, Ito N, Watanabe S, Yokoyama M, et al. Prevalence and characteristics of headaches in a socially active population working in the Tokyo metropolitan area -surveillance by an industrial health consortium. Intern Med. 2014;53(7):683–9.
Steiner TJ, Stovner LJ, Katsarava Z, Lainez JM, Lampl C, Lantéri-Minet M, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Barré J, Andrée C. The impact of headache in Europe: principal results of the Eurolight project. J Headache Pain. 2014;15:31.
Lampl C, et al. Headache, depression and anxiety: associations in the Eurolight project. J Headache Pain. 2016;17:59.
Haag G, et al. Self-medication of migraine and tension-type headache: summary of the evidence-based recommendations of the deutsche Migräne und Kopfschmerzgesellschaft (DMKG), the deutsche Gesellschaft für Neurologie (DGN), the Österreichische Kopfschmerzgesellschaft (ÖKSG) and the Schweizerische Kopfwehgesellschaft (SKG). J Headache Pain. 2011;12(2):201–17.
Fernando Prieto Peres M, et al. Non-pharmacological treatment for primary headaches prevention and lifestyle changes in a low-income Community of Brazil: a randomized clinical trial. Headache. 2019;59:86–96.
Eysenbach G. Infodemiology and infoveillance: framework for an emerging set of public health informatics methods to analyze search, communication and publication behavior on the internet. J Med Internet Res. 2009;1:e11.
Vo P, et al. Burden of migraine in Europe using self-reported digital diary data from the migraine buddy© application. Neurol Ther. 2018;7(2):321–32.
Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343–9.
Adams AM, Serrano D, Buse DC, et al. The impact of chronic migraine: the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia. 2015;35(7):563–78.
Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629–808.
Murray C, Vos T, Lozano R, Naghavi M, Flaxman A, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2010;380:2197–223.
Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the migraine disability assessment (MIDAS) questionnaire to assess headache-related disability. Neurology. 2001;56(suppl 1):S20–8.
Kosinski M, Bayliss MS, Bjorner JB, Ware JE, Garber WH, Batenhorst A, et al. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res. 2003;12:963–74.
Jacobson GP, Ramadan NM, Aggarwal SK, Newman CW. The Henry ford hospital headache disability inventory (HDI). Neurology. 1994;44:837.
El Hasnaoui A, Vray M, Richard A, Nachit-Ouinekh F, Boureau F, MIGSEV Group. Assessing the severity of migraine: development of the MIGSEV scale. Headache. 2003;43:628–35.
Wacogne C, Lacoste JP, Guillibert E, Hugues FC, Le Jeunne C. Stress, anxiety, depression and migraine. Cephalalgia. 2003;23(6):451–5.
Eskin M, Akyol A, Celik EY, Gultekin BK. Social problem-solving, perceived stress, depression and life-satisfaction in patients suffering from tension type and migraine headaches. Scand J Psychol. 2013;54(4):337–43.
Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia. 2007;27(5):394–402.
Park JW, Chu MK, Kim JM, Park SG, Cho SJ. Analysis of trigger factors in episodic migraineurs using a smartphone headache diary applications. PLoS One. 2016;11(2):e0149577.
Lipton RB, Bigal ME, Ashina S, Burstein R, Silberstein S, Reed ML, Serrano D, Stewart WF. Cutaneous allodynia in the migraine population. Ann Neurol. 2008;63(2):148–58.
Lee J, Shin C, Ko YH, Lim J, Joe SH, Kim S, Jung IK, Han C. The reliability and validity studies of the Korean version of the Perceived Stress Scale. Korean J Psychosom Med. 2012;20(2):127–34.
Lee HS, Chung CS, Song HJ, Park HS. The reliability and validity of the MIDAS (Migraine Disability Assessment) Questionnaire for Korean migraine sufferers. J Korean Neurol Assoc. 2000;18(3):287–91.
Seo JG, Park SP. Validation of the Patient Health Questionnaire-9 (PHQ-9) and PHQ-2 in patients with migraine. J Headache Pain. 2015;16(1):65.
Seo JG, Park SP. Validation of the Generalized Anxiety Disorder-7 (GAD-7) and GAD-2 in patients with migraine. J Headache Pain. 2015;16(1):97.
Cho YW, Lee JH, Son HK, Lee SH, Shin C, Johns MW. The reliability and validity of the Korean version of the Epworth sleepiness scale. Sleep Breath. 2011;15(3):377–84.
Cho YW, Song ML, Morin CM. Validation of a Korean version of the insomnia severity index. J Clin Neurol. 2014;10(3):210–5.
Martin BC, Pathak DS, Sharfman MI, Adelman JU, Taylor F, Kwong WJ, Jhingran P. Validity and Reliability of the Migraine-Specific Quality of Life Questionnaire (MSQ Version 2.1). Headache. 2000;40(3):204–16.
Zenebe Zewde Y, Zebenigus M, Demissie H, Tekle-Haimanot R, Uluduz D, Şaşmaz T, Bozdag F, Steiner TJ. The prevalence of headache disorders in children and adolescents in Ethiopia: a schools-based study. J Headache Pain. 2020;21(1):108. https://doi.org/10.1186/s10194-020-01179-2.
Luvsannorov O, Anisbayar T, Davaasuren M, Baatar O, Batmagnai K, Tumurbaatar K, Enkhbaatar S, Uluduz D, Şaşmaz T, Solmaz ET, Steiner TJ. The prevalence of headache disorders in children and adolescents in Mongolia: a nationwide schools-based study. J Headache Pain. 2020;21(1):107. https://doi.org/10.1186/s10194-020-01175-6.
Lifting The Burden. http://www.l-t-b.org . Accessed 17 Dec 2020.
Steiner TJ, Lipton RB, on behalf of Lifting The Burden: The Global Campaign against Headache. The headache-attributed lost time (HALT) indices: measures of burden for clinical management and population-based research. J Headache Pain. 2018;19(1):12. https://doi.org/10.1186/s10194-018-0837-3.
Ravens-Sieberer U, Bullinger M. Assessing health-related quality of life in chronically ill children with the German KINDL: first psychometric and content analytical results. Qual Life Res. 1998;7(5):399–407. https://doi.org/10.1023/A:1008853819715.
Hunfeld JA, Perquin CW, Duivenvoorden HJ, Hazebroek-Kampschreur AA, Passchier J, van Suijlekom-Smit LW, van der Wouden JC. Chronic pain and its impact on quality of life in adolescents and their families. J Pediatr Psychol. 2001;26(3):145–53.
Wöber C, Wöber-Bingöl C. Clinical management of young patients presenting with headache. Funct Neurol. 2000;15:89–105.
Leonardi M, Raggi A. A narrative review on the burden of migraine: when the burden is the impact on people's life. J Headache Pain. 2019;20(1):41.
Al-Hashel JY, Ahmed SF, Alroughani R. Prevalence and burden of primary headache disorders in Kuwaiti children and adolescents: a community based study. Front Neurol. 2019;10:793.
Cavestro C, Montrucchio F, Benci P, Pompilio D, Mandrino S, Cencio PG, Frigeri MC, Di Pietrantonj C. Headache prevalence and related symptoms, family history, and treatment habits in a representative population of children in Alba, Italy. Pediatr Neurol. 2014;51(3):348–53.
van den Maagdenberg AM. Migraine genetics: New opportunities, new challenges. Cephalalgia. 2016;36(7):601–3.
Hershey AD, Powers SW, Vockell AL, LeCates SL, Segers A, Kabbouche MA. Development of a patient-based grading scale for PedMIDAS. Cephalalgia. 2004;24(10):844–9.
Virtanen R, Aromaa M, Koskenvuo M, Sillanpää M, Pulkkinen L, Metsähonkala L, Suominen S, Rose RJ, Helenius H, Kaprio J. Externalizing problem behaviors and headache: a follow-up study of adolescent Finnish twins. Pediatrics. 2004;114(4):981–7.
GBD 2015 DALYs and HALE Collaborators, NJ AM, Barber RM, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1603–58. https://doi.org/10.1016/S0140-6736(16)31460-X.
Edmeads J, Mackell JA. The economic impact of migraine: an analysis of direct and indirect costs. Headache. 2002;42:501–9.
Bloudek LM, Stokes M, Buse DC, Wilcox TK, Lipton RB, Goadsby PJ, et al. Cost of healthcare for patients with migraine in five European countries: results from the international burden of migraine study (IBMS). J Headache Pain. 2012;13(5):361–78.
De Matteis E, Guglielmetti M, Ornello R, Spuntarelli V, Martelletti P, Sacco S. Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives. Expert Rev Neurother. 2020;20(6):627–41. https://doi.org/10.1080/14737175.2020.1772758.
Negro A, Sciattella P, Rossi D, Guglielmetti M, Martelletti P, Mennini FS. Cost of chronic and episodic migraine patients in continuous treatment for two years in a tertiary level headache Centre. J Headache Pain. 2019;20(1):120. https://doi.org/10.1186/s10194-019-1068-y.
Mecklenburg J, Raffaelli B, Neeb L, Sanchez Del Rio M, Reuter U. The potential of lasmiditan in migraine. Ther Adv Neurol Disord. 2020;13:1756286420967847. https://doi.org/10.1177/1756286420967847.
Raffaelli B, Neeb L, Reuter U. Monoclonal antibodies for the prevention of migraine. Expert Opin Biol Ther. 2019;19(12):1307–17. https://doi.org/10.1080/14712598.2019.1671350.
Tiseo C, Ornello R, Pistoia F, Sacco S. How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice. J Headache Pain. 2019;20(1):49. https://doi.org/10.1186/s10194-019-1000-5.
Steiner TJ, Antonaci F, Jensen R, Lainez MJ, Lanteri-Minet M, Valade D. Recommendations for headache service organisation and delivery in Europe. J Headache Pain. 2011;12(4):419–26. https://doi.org/10.1007/s10194-011-0320-x.
Agosti R. Migraine burden of disease: from the patient’s experience to a socio-economic view. Headache. 2018;58:17–32.
Sakai F, Igarashi H. Prevalence of migraine in Japan: a nationwide survey. Cephalalgia. 1997;17(1):15–22.
Bonafede M, Sapra S, Shah N, Tepper S, Cappell K, Desai P. Direct and indirect healthcare resource utilization and costs among migraine patients in the United States. Headache. 2018;58(5):700–14.
Silberstein S, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337–45.
Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force. Eur J Neurol. 2009;16(9):968–81.
Sanderson JC, Devine EB, Lipton RB, et al. Headache-related health resource utilisation in chronic and episodic migraine across six countries. J Neurol Neurosurg Psychiatry. 2013;84(12):1309–17.
Public Policy Committee. International Society of Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf. 2016;25:2–10.
Scher AI, Stewart WF, Lipton RB. Migraine and headache: a meta-analytic approach. In: Crombie IK, editor. Epidemiology of pain. WA: IASP press; 1999. p. 159–70.
Al-Hashel J, Ahmed SF, Alroughani R. Prevalence of primary headache disorders in Kuwait. Neuroepidemiology. 2017;48:138–46.
Steiner TJ, Gururaj G, Andrée C, Katsarava Z, Ayzenberg ISYY, Al Jumah M, Tekle-Haimanot R, Birbeck GL, Herekar A, Linde M, Mbewe E, Manandhar K, Risal A, Jensen R, Queiroz LP, Scher AI, Wang SJ, Stovner LJ. Diagnosis, prevalence estimation and burden measurement in population surveys of headache: presenting the HARDSHIP questionnaire. J Headache Pain. 2014;15:30.
Bener A. Frequency of headache and migraine in Qatar. Neuroepidemiology. 2006;27:61–6.
Deleu D, Khan MA, Al Shehab TA. Prevalence and clinical characteristics of headache in a rural community in Oman. Headache. 2002;42:963–73.
Ertas M, Baykan B, Orhan EK, Zarifoglu M, Karli N, Saip S, Onal A, Siva A. One-year prevalence and the impact of migraine and tension-type headache in Turkey: a nationwide home-based study in adults. J Headache Pain. 2012;13:147–57.
Rueda-Snchez M, daz-Martnez LA. Prevalence and associated factors for episodic and chronic daily headache in the Colombian population. Cephalalgia. 2008;28(3):216–25.
Allena M, Steiner TJ, Sances G, et al. Impact of headache disorders in Italy and the public-health and policy implications: a population-based study within the Eurolight project. J Headache Pain. 2015;16:100. https://doi.org/10.1186/s10194-015-0584-7.
Sillanpää M, Andlin-Sobocki P, Lönnqvist J. Costs of brain disorders in Finland. Acta Neurol Scand. 2008;117:167–72.
Martelletti P, Schwedt TJ, Lanteri-Minet M, et al. My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. J Headache Pain. 2018;19(1):115.
Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML, Turkel CC, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention study. Headache. 2012;52(10):1456–70.
Payne KA, Varon SF, Kawata AK, et al. The international burden of migraine study (IBMS): study design, methodology, and baseline cohort characteristics. Cephalalgia. 2011;31(10):1116–30.
Andrée C, Stovner LJ, Steiner TJ, Barré J, Katsarava Z, Lainez JM, Lair M-L, Lanteri-Minet M, Mick G, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Vriezen P, Lampl C. The Eurolight project: the impact of primary headache disorders in Europe. Description of methods. J Headache Pain. 2011;12:541–9.
Silberstein SD, Lee L, Gandhi K, Fitzgerald T, Bell J, Cohen JM. Health care resource utilization and migraine disability along the migraine continuum among patients treated for migraine. Headache. 2018;58:1579–92.
Ford JH, Schroeder K, Nyhuis AW, Foster SA, Aurora SK. Cycling through migraine preventive treatments: implications for all-cause Total direct costs and disease-specific costs. J Manag Care Spec Pharm. 2018;25:1–12. https://doi.org/10.18553/jmcp.2018.18058.
Honkasalo ML, Kaprio J, Heikkilä K, Sillanpää M, Koskenvuo M. A population-based survey of headache and migraine in 22,809 adults. Headache. 1993;33:403–12.
Raggi A, Leonardi M. Burden and cost of neurological diseases: a European north–south comparison. Acta Neurol Scand. 2015;132:16–22.
Munakata J, Hazard E, Serrano D, et al. Economic burden of transformed migraine: results from the American migraine prevalence and prevention (AMPP) study. Headache. 2009;49:498–508.
Mbewe E, Zairemthiama P, Paul R, Birbeck GL, Steiner TJ. The burden of primary headache disorders in Zambia: national estimates from a population-based door-to-door survey. J Headache Pain. 2015;16:36.
World Health Organization, Burden LT. Atlas of headache disorders and resources in the world 2011. Geneva: WHO; 2011.
Salomon JA, Haagsma JA, Davis A, de Noordhout CM, Polinder S, Havelaar AH, Cassini A, Devleesschauwer B, Kretzschmar M, Speybroeck N, Murray CJ, Vos T. Disability weights for the Global Burden of Disease 2013 study. Lancet Glob Health. 2015;3:e712–23. https://doi.org/10.1016/S2214-109X(15)00069-8.
Wateraid UK. Where we work 2017. http://www.Wateraid.Org/Uk/Where-we-work/page/ethiopia (last accessed 3.2.17).
Shahbeigi S, Fereshtehnejad S-M, Mohammadi N, et al. Epidemiology of headaches in Tehran urban area: a population-based cross-sectional study in district 8, year 2010. Neurol Sci. 2013;34(7):1157–66. https://doi.org/10.1007/s10072-012-1200-0.
Ayatollahi SMT, Moradi F, Ayatollahi SAR. Prevalences of migraine and tension-type headache in adolescent girls of shiraz (southern Iran). Headache. 2002;42(4):287–90. http://www.ncbi.nlm.nih.gov/pubmed/12010386. Accessed November 16, 2018
Fallahzadeh H, Alihaydari M. Prevalence of migraine and tension-type headache among school children in Yazd, Iran. J Pediatr Neurosci. 2011;6(2):106–9. https://doi.org/10.4103/1817-1745.92818.
Romdhane NA, Ben Hamida M, Mrabet A, et al. Prevalence study of neurologic disorders in Kelibia (Tunisia). Neuroepidemiology. 1993;12(5):285–99. https://doi.org/10.1159/000110330.
Bener A, Swadi H, Qassimi EM, Uduman S. Prevalence of headache and migraine in schoolchildren in the United Arab Emirates. Ann Saudi Med. 18(6):522–4. http://www.ncbi.nlm.nih.gov/pubmed/17344729. Accessed 16 Nov 2018
Bahrami P, Zebardast H, Zibaei M, Mohammadzadeh M, Zabandan N. Prevalence and characteristics of headache in Khoramabad, Iran. Pain Physician. 15(4):327–32. http://www.ncbi.nlm.nih.gov/pubmed/22828686. Accessed 16 Nov 2018
Bessisso MS, Bener A, Elsaid MF, Al-Khalaf FA, Huzaima KA. Pattern of headache in school children in the State of Qatar. Saudi Med J. 2005;26(4):566–70. http://www.ncbi.nlm.nih.gov/pubmed/15900361. Accessed 16 Nov 2018
Free 2018 ICD-10-CM Codes. https://www.icd10data.com/ICD10CM/Codes. Accessed 4 June 2018.
Abu-Arafeh I, Razak S, Sivaraman B, Graham C. Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies. Dev Med Child Neurol. 2010;52(12):1088–97.
Wöber-Bingöl C. Epidemiology of migraine and headache in children and adolescents. Curr Pain Headache Rep. 2013;17(6):341.
Heinrich M, Morris L, Kröner-Herwig B. Self-report of headache in children and adolescents in Germany: possibilities and confines of questionnaire data for headache classification. Cephalalgia. 2009;29(8):864–72.
Anttila P, Metsähonkala L, Aromaa M, Sourander A, Salminen J, Helenius H, et al. Determinants of tension-type headache in children. Cephalalgia. 2002;22(5):401–8.
Pothmann R, Frankenberg SV, Muller B, Sartory G, Hellmeier W. Epidemiology of headache in children and adolescents: evidence of high prevalence of migraine. Int J Behav Med. 1994;1(1):76–89.
Antonaci F, Voiticovschi-Iosob C, Di Stefano AL, Galli F, Ozge A, Balottin U. The evolution of headache from childhood to adulthood: a review of the literature. J Headache Pain. 2014;15:15.
Karwautz A, Wöber C, Lang T, Böck A, Wagner-Ennsgraber C, Vesely C, et al. Psychosocial factors in children and adolescents with migraine and tension-type headache: a controlled study and review of the literature. Cephalalgia. 1999;19(1):32–43.
Juang K-D, Wang S-J, Fuh J-L, Lu S-R, Chen Y-S. Association between adolescent chronic daily headache and childhood adversity: a community-based study. Cephalalgia. 2004;24(1):54–9.
Kröner-Herwig B, Heinrich M, Morris L. Headache in German children and adolescents: a population-based epidemiological study. Cephalalgia. 2007;27(6):519–27.
Bugdayci R, Ozge A, Sasmaz T, Kurt AO, Kaleagasi H, Karakelle A, et al. Prevalence and factors affecting headache in Turkish schoolchildren. Pediatr Int. 2005;47(3):316–22.
GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017;16(11):877–97.
Rice ASC, Smith BH, Blyth FM. Pain and the global burden of disease. Pain. 2016;157:791–6.
Malta DC, Bernal RTI, Lima MG, Araújo SSC, MMAD S, MIDF F, et al. Noncommunicable diseases and the use of health services: analysis of the National Health Survey in Brazil. Rev Saude Publica. 2017;51(suppl 1):4s.
Lampe F. Validity of a self-reported history of doctor-diagnosed angina. J Clin Epidemiol. 1999;52:73–81.
Ramos RQ, Bastos JL, Peres MA. Diagnostic validity of self-reported oral health outcomes in population surveys: literature review. Rev Bras Epidemiol. 2013;16:716–28.
Chrestani MAD, Santos Ida S, Matijasevich AM. Self-reported hypertension: validation in a representative cross-sectional survey. Cad Saude Publica. 2009;25:2395–406.
Moreira NF, Luz VG, Moreira CC, Pereira RA, Sichieri R, Ferreira MG, et al. Self-reported weight and height are valid measures to determine weight status: results from the Brazilian National Health Survey (PNS 2013). Cad Saude Publica. 2018;34:(S)1-13.
Queiroz LP, Peres MFP, Piovesan EJ, Kowacs F, Ciciarelli MC, Souza JA, et al. A nationwide population-based study of migraine in Brazil. Cephalalgia. 2009;29:642–9.
Queiroz LP, Peres MFP, Piovesan EJ, Kowacs F, Ciciarelli MC, Souza JA, et al. A nationwide population-based study of tension-type headache in Brazil. Headache. 2009;49:71–8.
Queiroz LP, Peres MFP, Kowacs F, Piovesan EJ, Ciciarelli MC, Souza JA, et al. Chronic daily headache in Brazil: a nationwide population-based study. Cephalalgia. 2008;28:1264–9.
International Headache Society Classification Subcommittee. The international classification of headache disorders. Cephalalgia. 2014;24(suppl 1):1–160. 2nd edition
Stewart W, Lipton R, Kolodner K, Sawyer J, Lee C, Liberman J. Validity of the migraine disability assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain. 2000;88(1):41–52.
Lucchetti G, Peres MFP. The prevalence of migraine and probable migraine in a Brazilian favela: results of a community survey. Headache. 2011;51:971–9.
Goulart AC, Santos IS, Brunoni AR, Nunes MA, Passos VM, Griep RH, et al. Migraine headaches and mood/anxiety disorders in the ELSA Brazil. Headache. 2014;54:1310–9.
Queiroz LP, Silva Junior AA. The prevalence and impact of headache in Brazil. Headache. 2015;55:32–8.
Krogh AB, Larsson B, Linde M. Prevalence and disability of headache among Norwegian adolescents: a cross-sectional school-based study. Cephalalgia. 2015;35:1181–91.
Chong SC, Chan YH, Ong HT, Low PS, Tay SK. Headache diagnosis, disability and co-morbidities in a multi-ethnic, heterogeneous paediatric Asian population. Cephalalgia. 2010;30:953–61.
Kong CK, Cheng WW, Wong LY. Epidemiology of headache in Hong Kong primary-level schoolchildren: questionnaire study. Hong Kong Med J. 2001;7:29–33.
Rho YI, Chung HJ, Lee KH, Eun BL, Eun SH, Nam SO, et al. Prevalence and clinical characteristics of primary headaches among school children in South Korea: a nationwide survey. Headache. 2012;52(4):592–9.
Hublin C, Kaprio J, Partinen M, Koskenvuo M. Insufficient sleep--a population-based study in adults. Sleep. 2001;24(4):392–400.
Holt JB, Zhang X, Sizov N, Croft JB. Airport noise and self-reported sleep insufficiency, United States, 2008 and 2009. Prev Chronic Dis. 2015;12:E49.
Cho SJ, Chung YK, Kim JM, Chu MK. Migraine and restless legs syndrome are associated in adults under age fifty but not in adults over fifty: a population-based study. J Headache Pain. 2015;16:554.
Song TJ, Cho SJ, Kim WJ, Yang KI, Yun CH, Chu MK. Anxiety and depression in probable migraine: A population-based study. Cephalalgia. 2017;37(9):845–54.
Oh K, Cho SJ, Chung YK, Kim JM, Chu MK. Combination of anxiety and depression is associated with an increased headache frequency in migraineurs: a population-based study. BMC Neurol. 2014;14:238.
Wijeratne T, Grisold W, Dodick D, Carroll W. World brain day 2019: migraine, the painful truth. Lancet Neurol. 2019;18(10):914. https://doi.org/10.1016/S1474-4422(19)30281-9.
Lipton RB, Manack Adams A, Buse DC, Fanning KM, Reed ML. A comparison of the chronic migraine epidemiology and outcomes (CaMEO) study and American Migraine Prevalence and Prevention (AMPP) study: demographics and headache-related disability. Headache. 2016;56(8):1280–9. https://doi.org/10.1111/head.12878.
Buse DC, Fanning KM, Reed ML, Murray S, Dumas PK, Adams AM, Lipton RB. Life with migraine: effects on relationships, career, and finances from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache. 2019;59(8):1286–99. https://doi.org/10.1111/head.13613.
Song TJ, Cho SJ, Kim WJ, Yang KI, Yun CH, Chu MK. Sex differences in prevalence, symptoms, impact, and psychiatric comorbidities in migraine and probable migraine: a population-based study. Headache. 2019;59(2):215–23. https://doi.org/10.1111/head.13470.
Takeshima T, Wan Q, Zhang Y, Komori M, Stretton S, Rajan N, et al. Prevalence, burden, and clinical management of migraine in China, Japan, and South Korea: a comprehensive review of the literature. J Headache Pain. 2019;20:111.
Wang SJ, Chung CS, Chankrachang S, Ravishankar K, Merican JS, Salazar G, Siow C, Cheung RT, Phanthumchinda K, Sakai F. Migraine disability awareness campaign in Asia: migraine assessment for prophylaxis. Headache. 2008;48:1356–65.
Ueda K, Ye W, Lombard L, Kuga A, Kim Y, Cotton S, et al. Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme. J Headache Pain. 2019;20(1):68.
Liu R, Yu S, He M, Zhao G, Yang X, Qiao X, et al. Health-care utilization for primary headache disorders in China: a population-based door-to-door survey. J Headache Pain. 2013;14:47.
Bagley CL, Rendas-Baum R, Maglinte GA, Yang M, Varon SF, Lee J, et al. Validating migraine-specific quality of life questionnaire v2.1 in episodic and chronic migraine. Headache. 2012;52(3):409–21.
Jo NJ, Kim BK. Clinical characteristics of migraine with Aura in Korean: a clinic based study. J Korean Neurol Assoc. 2015;33(4):278–81. https://doi.org/10.17340/jkna.2015.4.6.
Dodick DW, Loder EW, Manack Adams A, Buse DC, Fanning KM, Reed ML, Lipton RB. Assessing barriers to chronic migraine consultation, diagnosis, and treatment: results from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache. 2016;56(5):821–34. https://doi.org/10.1111/head.12774.
Katsarava Z, Mania M, Lampl C, Herberhold J, Steiner TJ. Poor medical care for people with migraine in Europe—evidence from the Eurolight study. J Headache Pain. 2018;19:10.
Lipton RB, Buse DC, Serrano D, Holland S, Reed ML. Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2013;53(8):1300–11. https://doi.org/10.1111/head.12154.
Rao GN, Kulkarni GB, Gururaj G, Stovner LJ, Steiner TJ. The burden attributable to headache disorders in India: estimates from a community-based study in Karnataka state. J Headache Pain. 2015;16:94.
Manandhar K, Risal A, Linde M, Steiner TJ. The burden of headache disorders in Nepal: estimates from a population-based survey. J Headache Pain. 2016;17:3.
Herekar AD, Herekar AA, Ahmad A, Uqaili UL, Ahmed B, Effendi J, Alvi SZ, Steiner TJ. The burden of headache disorders in Pakistan: methodology of a population-based nationwide study, and questionnaire validation. J Headache Pain. 2013;14:73.
Zebenigus M, Tekle-Haimanot R, Worku DK, Thomas H, Steiner TJ. The burden of headache disorders in Ethiopia: national estimates from a population-based door-to-door survey. J Headache Pain. 2017;18:58.
Ayzenberg I, Katsarava Z, Sborowski A, Chernysh M, Osipova V, Tabeeva G, Steiner TJ. Headache-attributed burden and its impact on productivity and quality of life in Russia: structured healthcare for headache is urgently needed. Eur J Neurol. 2014;21:758–65.
Rastenytė D, Mickevičienė D, Stovner LJ, Thomas H, Andrée C, Steiner TJ. Prevalence and burden of headache disorders in Lithuania and their public-health and policy implications: a population-based study within the Eurolight project. J Headache Pain. 2017;18:53.
Allena M, Steiner TJ, Sances G, Carugno B, Balsamo F, Nappi G, Andrée C, Tassorelli C. Impact of headache disorders in Italy and the public-health and policy implications: a population-based study within the Eurolight project. J Headache Pain. 2015;16:100.
Selekler MH, Gökmen G, Steiner TJ. Productivity impact of headache on a heavy-manufacturing workforce in Turkey. J Headache Pain. 2013;14:88.
Selekler HM, Gökmen G, Alvur TM, Steiner TJ. Productivity losses attributable to headache, and their attempted recovery, in a heavy-manufacturing workforce in Turkey: implications for employers and politicians. J Headache. 2015;16:96.
Katsarava Z, Gil Gouveia R, Jensen R, Gaul C, Schramm S, Schoppe A, Steiner TJ. Evaluation of headache service quality indicators: pilot implementation in two specialist-care centres. J Headache Pain. 2015;16:53.
Schramm S, Uluduz D, Gil Gouveia R, Jensen R, Siva A, Uygunoglu U, Gvantsa G, Mania M, Braschinsky M, Filatova E, Latysheva N, Osipova V, Skorobogatykh K, Azimova J, Straube A, Emre Eren O, Martelletti P, De Angelis V, Negro A, Linde M, Hagen K, Radojicic A, Zidverc-Trajkovic J, Podgorac A, Paemeleire K, De Pue A, Lampl C, Steiner TJ, Katsarava Z. Headache service quality: evaluation of quality indicators in 14 specialist-care centres. J Headache Pain. 2016;17:111.
Braschinsky M, Haldre S, Kals M, Iofik A, Kivisild A, Korjas J, Koljal S, Katsarava Z, Steiner TJ. Structured education can improve primary-care management of headache: the first empirical evidence, from a controlled interventional study. J Headache Pain. 2016;17:24.
Braschinsky M, Haldre S, Kals M, Arge M, Saar B, Niibek M, Katsarava Z, Steiner TJ. Structured education to improve primary-care management of headache: how long do the benefits last? A follow-up observational study. Eur J Neurol. 2018;25(3):497–502.
Steiner TJ. The HALT and HART indices. J Headache Pain. 2007;8(suppl 1):S22–5.
Stovner LJ, Al Jumah M, Birbeck GL, Gururaj G, Jensen R, Katsarava Z, Queiroz LP, Scher AI, Tekle-Haimanot R, Wang SJ, Steiner TJ. The methodology of population surveys of headache prevalence, burden and cost: principles and recommendations from the global campaign against headache. J Headache Pain. 2014;15:5.
Eiser C, Morse R. Quality-of-life measures in chronic diseases of childhood. Health Technol Assess. 2001;5(4):1–157.
Raggi A, Covelli V, Schiavolin S, Giovannetti AM, Cerniauskaite M, Quintas R, Leonardi M, Sabariego C, Grazzi L, D’Amico D. Psychosocial difficulties in patients with episodic migraine: a cross-sectional study. Neurol Sci. 2016;37(12):1979–86.
Juang KD, Wang SJ, Fuh JL, Lu SR, Su TP. Comorbidity of depressive and anxiety disorders in chronic daily headache and its subtypes. Headache. 2000;40:818–23.
Lipton R, Liberman J, Kolodner K, et al. Migraine headache disability and health-related quality-of-life: a population-based case-control study from England. Cephalalgia. 2003;23:441–50. https://doi.org/10.1046/j.1468-2982.2003.00546.x.
Bigal ME, Rapoport AM, Lipton RB, et al. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache. 2003;43:336–42.
Gelfand A. Pathophysiology, clincal features, and diagnosis of migraine in children [internet]. UpToDate, Wolters Kluwer. 2017. p. 1–13. https://www.uptodate.com/contents/pathophysiology-clinical-features-and-diagnosis-of-migraine-in-children
Wöber-Bingöl C, Wöber C, Wagner-Ennsgraber C, Zebenholzer K, Vesely C, Geldner J, et al. IHS criteria and gender: a study on migraine and tension-type headache in children and adolescents. Cephalalgia. 1996;16(2):107–12.
Dooley JM, Gordon KE, Wood EP. Self-reported headache frequency in Canadian adolescents: validation and follow-up. Headache. 2005;45(2):127–31.
Özge A, Şaşmaz T, Buǧdayci R, Çakmak SE, Kurt AÖ, Kaleaǧasi SH, et al. The prevalence of chronic and episodic migraine in children and adolescents. Eur J Neurol. 2013;20(1):95–101.
Casucci G, Terlizzi R, Cevoli S. Headache in school age. Neurol Sci. 2014;35(SUPPL. 1):31–5.
Millichap GJ, Yee MM. The diet factor in pediatric and adolescent migraine. Pediatr Neurol. 2003;28:9–15.
Robberstad L, Dyb G, Hagen K, Stovner LJ, Holmen TL, Zwart JA. An unfavorable lifestyle and recurrent headaches among adolescents: the HUNT study. Neurology. 2010;75(8):712–7.
Hershey AD, Powers SW, Nelson TD, Kabbouche MA, Winner P, Yonker M, et al. Obesity in the pediatric headache population: a multicenter study. Headache. 2009;49(2):170–7.
Isik U, Ersu RH, Ay P, Save D, Arman AR, Karakoc F, et al. Prevalence of headache and its association with sleep disorders in children. Pediatr Neurol. 2007;36(3):146–51.
Casez O, Dananchet Y, Besson G. Migraine and somnambulism. Neurology. 2005;65(8):1334–5.
Milde-Busch A, Blaschek A, Borggräfe I, Heinen F, Straube A, Von Kries R. Associations of diet and lifestyle with headache in high-school students: results from a cross-sectional study. Headache. 2010;50(7):1104–14.
Moschiano F, Messina P, D’Amico D, Grazzi L, Frediani F, Casucci G, et al. Headache, eating and sleeping behaviors and lifestyle factors in preadolescents and adolescents: preliminary results from an Italian population study. Neurol Sci. 2012;33(SUPPL. 1):S87–90.
Chakravarty A, Mukherjee A, Roy D. Trigger factors in childhood migraine: a clinic-based study from eastern India. J Headache Pain. 2009;10(5):375–80.
Connelly M, Miller T, Gerry G, Bickel J. Research submission electronic momentary assessment of weather changes as a trigger of headaches in children. Headache. 2010;50:779–89.
Russo A, Bruno A, Trojsi F, Tessitore A, Tedeschi G. Lifestyle factors and migraine in childhood. Curr Pain Headache Rep. 2016;20(2):9.
Varni J, Burwinkle T, Seid M, Skarr D. The PedsQL™ 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pediatr. 2003;3(6):329–41.
Neut D, Fily A, Cuvellier JC, Vallée L. The prevalence of triggers in paediatric migraine: a questionnaire study in 102 children and adolescents. J Headache Pain. 2012;13(1):61–5.
Solotareff L, Cuvellier JC, Duhamel A, Vallée L, Tich SNT. Trigger factors in childhood migraine: a prospective clinic-based study from north of France. J Child Neurol. 2017;32(8):754–8.
Todd C, Lagman-Bartolome AM, Lay C. Women and migraine: the role of hormones. Curr Neurol Neurosci Rep. 2018;18(7):42.
Martin VT, Behbehani M. Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis--part 2. Headache. 2006;46(3):365–86.
Martin VT, Pavlovic J, Fanning KM, Buse DC, Reed ML, Lipton RB. Perimenopause and menopause are associated with high frequency headache in women with migraine: results of the American Migraine Prevalence and Prevention study. Headache. 2016;56(2):292–305.
Pavlovic JM, Allshouse AA, Santoro NF, Crawford SL, Thurston RC, Neal-Perry GS, et al. Sex hormones in women with and without migraine: evidence of migraine-specific hormone profiles. Neurology. 2016;87(1):49–56.
Murialdo G, Martignoni E, De Maria A, Bonura ML, Sances G, Bono G, et al. Changes in the dopaminergic control of prolactin secretion and in ovarian steroids in migraine. Cephalalgia. 1986;6(1):43–9.
Epstein MT, Hockaday JM, Hockaday TD. Migraine and reproductive hormones throughout the menstrual cycle. Lancet. 1975;1(7906):543–8.
van Oosterhout WPJ, Schoonman GG, van Zwet EW, Dekkers OM, Terwindt GM, MaassenVanDenBrink A, et al. Female sex hormones in men with migraine. Neurology. 2018;91(4):e374–ee81.
Cobey KD, Buunk AP, Roberts SC, Klipping C, Appels N, Zimmerman Y, Bennink HJTC, Pollet TV. Reported jealousy differs as a function of menstrual cycle stage and contraceptive pill use: a within-subjects investigation. Evol Hum Behav. 2012;33(4):395–401.
Cobey KD, Roberts SC, Buunk AP. Hormonal contraceptive congruency: implications for relationship jealousy. Pers Individ Differ. 2013;55:569–73.
Lantagne A, Furman W. Romantic relationship development: the interplay between age and relationship length. Dev Psychol. 2017;53(9):1738–49.
Murtaza M, Kisat M, Daniel H, Sonawalla AB. Classification and clinical features of headache disorders in Pakistan: a retrospective review of clinical data. PLoS One. 2009;4(6):e5827.
D’Amico D, Grazzi L, Curone M, Di Fiore P, Proietti Cecchini A, Leonardi M, et al. Difficulties in work activities and the pervasive effect over disability in patients with episodic and chronic migraine. Neurol Sci. 2015;36(Suppl 1):9–11.
Park JW, Shin HE, Kim JS, Lee KS. Assessing migraine disability by diary-based measurement: relationship to the characteristics of individual headache attacks. Eur J Neurol. 2008;15(8):817–21.
Nagpal M, Jangid R, Sathyanarayan RT. A comparative study of the sexual functioning of women with primary headache in India. Indian J Psychiatry. 2018;60(2):224–8. https://doi.org/10.4103/psychiatry.IndianJPsychiatry_290_17.
Blumenfeld A, Bloudek LM, Becker WJ, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013;53:644–55.
Stark RJ, Ravishankar K, Siow HC, Lee KS, Pepperle R, Wang SJ. Chronic migraine and chronic daily headache in the Asia-Pacific region: a systematic review. Cephalalgia. 2013;33(4):266–83.
Freitag FG. The cycle of migraine: patients’ quality of life during and between migraine attacks. Clin Ther. 2007;29(5):939–49.
Deb P, Norton EC. Modeling health care expenditures and use. Annu Rev Public Health. 2018;39(1):489–505.
ICF International, Philippine Statistics Authority. National Demographic and Health Survey 2017. Manila, Philippines and Rockville, Maryland, USA: PSA and ICF International; 2018.
Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012;16(1):86–92.
Bigal ME, Rapoport AM, Lipton RB, Tepper SJ, Sheftell FD. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: A comparison of chronic migraine with episodic migraine. Headache. 2003;43(4):336–42.
Bigal ME, Bordini CA, Sheftell FD, Speciali JG, Bigal JO. Migraine with aura versus migraine without aura: Pain intensity and associated symptom intensities after placebo. Headache. 2002;42(9):872–7.
Buse D, Manack A, Serrano D, Reed M, Varon S, Turkel C, et al. Headache impact of chronic and episodic migraine: Results from the American migraine prevalence and prevention study. Headache. 2012;52(1):3–17.
American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59(1):1–18.
Kawata AK, Coeytaux RR, Devellis RF, Finkel AG, Mann JD, Kahn K. Psychometric properties of the HIT-6 among patients in a headache-specialty practice. Headache. 2005;45(6):638–43.
Yang M, Rendas-Baum R, Varon SF, Kosinski M. Validation of the headache impact test (HIT-6) across episodic and chronic migraine. Cephalalgia. 2011;31(3):357–67.
Lipton RB, Kolodner K, Bigal ME, Valade D, Lainez MJ, Pascual J, et al. Validity and reliability of the migraine-treatment optimization questionnaire. Cephalalgia. 2009;29(7):751–9.
Smelt AF, Assendelft WJ, Terwee CB, Ferrari MD, Blom JW. What is a clinically relevant change on the HIT-6 questionnaire? An estimation in a primary-care population of migraine patients. Cephalalgia. 2014;34(1):29–36.
Rendas-Baum R, Yang M, Varon SF, Bloudek LM, DeGryse RE, Kosinski M. Validation of the headache impact test (HIT-6) in patients with chronic migraine. Health Quality Life Outcomes. 2014;12:117.
Bayliss MS, Batenhorst AS. The HIT-6™: A user’s guide. Lincoln, RI: QualityMetric Incorporated; 2002.
Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine. PROMISE-2. Neurology. 2020;94(13):e1365–77.
Ayer DW, Skljarevski V, Ford JH, Nyhuis AW, Lipton RB, Aurora SK. Measures of functioning in patients with episodic migraine: Findings from a double-blind, randomized, placebo-controlled phase 2b trial with galcanezumab. Headache. 2018;58(8):1225–35.
Bagley CL, Rendas-Baum R, Maglinte GA, Yang M, Varon SF, Lee J, et al. Validating migraine-specific quality of life questionnaire v2.1 in episodic and chronic migraine. Headache. 2011;52(3):409–21.
Cole JC, Lin P, Rupnow MF. Validation of the migraine-specific quality of life questionnaire version 2.1 (MSQ v. 2.1) for patients undergoing prophylactic migraine treatment. Qual Life Res. 2007;16(7):1231–7.
Kawata AK, Hsieh R, Bender R, Shaffer S, Revicki DA, Bayliss M, et al. Psychometric evaluation of a novel instrument assessing the impact of migraine on physical functioning: The migraine physical function impact diary. Headache. 2017;57(9):1385–98.
Sauro KM, Rose MS, Becker WJ, Christie SN, Giammarco R, Mackie GF, et al. HIT-6 and MIDAS as measures of headache disability in a headache referral population. Headache. 2010;50(3):383–95.
Sculpher MJ, Pang FS, Manca A, Drummond MF, Golder S, Urdahl H, et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess. 2004;8(49):iii–iv. 1–192
Augustovski F, Iglesias C, Manca A, Drummond M, Rubinstein A, Martí SG. Barriers to generalizability of health economic evaluations in Latin America and the Caribbean region. PharmacoEconomics. 2009;27(11):919–29.
Drummond M, Manca A, Sculpher M. Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies. Int J Technol Assess Health Care. 2005;21(2):165–71.
Ruggeri M, Manca A, Coretti S, Codella P, Iacopino V, Romano F, et al. Investigating the generalizability of economic evaluations conducted in Italy: a critical review. Value Health. 2015;18(5):709–20.
Yu J, Smith KJ, Brixner DI. Cost effectiveness of pharmacotherapy for the prevention of migraine. CNS Drugs. 2010;24(8):695–712.
Batty AJ, Hansen RB, Varon LF, Sepideh JH, Pennington EW, Lipton BR, et al. The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK. J Med Econ. 2013;16(7):877–87.
Sussman M, Benner J, Neumann P, Menzin J. Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: results from the US societal and payer perspectives. Cephalalgia. 2018;38(10):1644–57.
Lofland JH, Nash DB. Oral serotonin receptor agonists: a review of their cost effectiveness in migraine. PharmacoEconomics. 2005;23:259–74.
McCormack PL, Foster RH. Rizatriptan: a pharmacoeconomic review of its use in the acute treatment of migraine. PharmacoEconomics. 2005;23:1283–98.
Yu J, Goodman JM, Gary O. Economic evaluation of pharmacotherapy of migraine pain: a review of the literature. J Pain Palliat Care Pharmacother. 2009;23:396–408.
Ambrósio EM, Bloor K, Macpherson H. Costs and consequences of acupuncture as a treatment for chronic pain: a systematic review of economic evaluations conducted alongside randomised controlled trials. Complement Ther Med. 2012;20:364–74.
Hens M, Villaverde-Hueso A, Alonso V, Abaitua I, Posada de la Paz M. Comparative cost-effectiveness analysis of oral triptan therapy for migraine in four European countries. Eur J Health Econ. 2014;15(4):433–7.
Ruggeri M. The cost effectiveness of Botox in Italian patients with chronic migraine. Neurol Sci. 2014;35(Suppl. 1):45–7.
Lipton RB, Brennan A, Palmer S, Hatswell AJ, Porter JK, Sapra S, et al. Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. J Med Econ. 2018;21(7):666–75.
Mwamburi M, Tenaglia AT, Leibler EJ, Staats PS. Cost-effectiveness of noninvasive vagus nerve stimulation for acute treatment of episodic migraine and role in treatment sequence strategies. Am J Manag Care. 2018;24(24 Suppl):S527–33.
Slof J. Cost effectiveness analysis of early versus non-early intervention in acute migraine based on evidence from the “Act when mild” study. Appl Health Econ Health Policy. 2012;10(3):201–15.
Hollier-Hann G, Curry A, Onishchenko K, Akehurst R, Ahmed F, Davies B, et al. Updated cost-effectiveness analysis of onabotulinumtoxinA for the prevention of headache in adults with chronic migraine who have previously received three or more preventive treatments in the UK. J Med Econ. 2019;4:1–11.
Giannouchos TV, Mitsikostas DD, Ohsfeldt RL, Vozikis A, Koufopoulou P. Cost-effectiveness analysis of erenumab versus onabotulinumtoxinA for patients with chronic migraine attacks in Greece. Clin Drug Investig. 2019;39(10):979–90.
Shauly O, Gould DJ, Patel KM. Cost-utility analysis of surgical decompression relative to injection therapy for chronic migraine headaches. Aesthet Surg J. 2019;39(12):NP462–70.
Asseburg C, Peura P, Oksanen T, Turunen J, Purmonen T, Martikainen J. Cost-effectiveness of oral triptans for acute migraine: mixed treatment comparison. Int J Technol Assess Health Care. 2012;28(4):382–9.
World Bank List of Economies. http://www.databank.worldbank.org/data/download/site-content/CLASS.xls . June 2017.
Woldeamanuel YW, Cowan RP. Migraine affects 1 in 10 people worldwide featuring recent rise: a systematic review and meta-analysis of community-based studies involving 6 million participants. J Neurol Sci. 2017;372:307–15.
Masterson Creber RM, Smeeth L, Gilman RH, Miranda JJ. Physical activity and cardiovascular risk factors among rural and urban groups and rural-to-urban migrants in Peru: a cross-sectional study. Rev Panam Salud Publica. 2010;28(1):1–8.
Hallal PC, Andersen LB, Bull FC, Guthold R, Haskell W, Ekelund U, et al. Global physical activity levels: surveillance progress, pitfalls, and prospects. Lancet. 2012;380(9838):247–57.
Muthuri SK, Wachira LJ, Leblanc AG, Francis CE, Sampson M, Onywera VO, et al. Temporal trends and correlates of physical activity, sedentary behaviour, and physical fitness among school-aged children in Sub-Saharan Africa: a systematic review. Int J Environ Res Public Health. 2014;11(3):3327–59. This systematic review addresses the trends and correlates of physical inactivity in Africa. It describes the increasing health problem related to sedentary behavior in low-resource setting
Peltzer K. Health behavior and protective factors among school children in four African countries. Int J Behav Med. 2009;16(2):172–80.
Guthold R, Cowan MJ, Autenrieth CS, Kann L, Riley LM. Physical activity and sedentary behavior among schoolchildren: a 34-country comparison. J Pediatr. 2010;157(1):43–9.e1.
Al-Hashel JY, Ahmed SF, Alroughani R, Goadsby PJ. Migraine misdiagnosis as a sinusitis, a delay that can last for many years. J Headache Pain. 2013;14:97. This article describes that headache misdiagnosis are delayed by many years in low-resource settings
World Health Organization. Traditional medicine strategy 2002–2005. Rome: WHO; 2002.
NCD and the Sustainable Development Goals. WHO Global Coordination Mechanism on the Prevention and Control of NCDs. http://www.who.int/global-coordination-mechanism/ncd-themes/sustainable-development-goals/en/ .
Temu F, Leonhardt M, Carter J, Thiam S. Integration of non-communicable diseases in health care: tackling the double burden of disease in African settings. Pan Afr Med J. 2014;18:202.
GBD. Diseases and Injuries Collaborators (2020) Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2019;396(10258):1204–22. https://doi.org/10.1016/S0140-6736(20)30925-9.
Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z, on behalf of Lifting The Burden: the Global Campaign against Headache. Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137. https://doi.org/10.1186/s10194-020-01208-0.
Kothari SF, Jensen RH, Steiner TJ. The relationship between headache-attributed disability and lost productivity. 1. A review of the literature. J Headache Pain. 2021;22:73.
World Health Organization. WHO methods and data sources for global burden of disease estimates 2000–2015 (2017) Global Health Estimates Technical Paper WHO/HIS/IER/GHE/2017.1. https://www.who.int/healthinfo/global_burden_disease/GlobalDALYmethods_2000_2015.pdf (last accessed 22.10.21).
Radtke A, Neuhauser H. Prevalence and burden of headache and migraine in Germany. Headache. 2009;49:79–89. https://doi.org/10.1111/j.1526-4610.2008.01263.x.
Mennini FS, Gitto L, Martelletti P. Improving care through health economics analyses: cost of illness and headache. J Headache Pain. 2008;9:199–206.
Stokes M, Becker WJ, Lipton RB, et al. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the international burden of migraine study (IBMS). Headache. 2011;51:1058–77. https://doi.org/10.1111/j.1526-4610.2011.01945.x.
Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, CDBE2010Study group, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(10):718–79.
Deloitte. Migraine in Australia whitepaper. Prepared for Novartis Australia by Deloitte access economics 2018. https://www2.deloitte.com/au/en/pages/economics/articles/migraine-australia-whitepaper.html . Accessed 8 Jan 2019.
Stewart WF, Wood GC, Manack A, Varon SF, Buse DC, Lipton RB. Employment and work impact of chronic migraine and episodic migraine. J Occup Environ Med. 2010;52(1):8–14. https://doi.org/10.1097/JOM.0b013e3181c1dc56.
Centrālās Statistikas Pārvaldes Datubāses. IKG10_010. Total gross domestic product, per capita and per person employed. https://data1.csb.gov.lv/pxweb/en/ekfin/ekfin__ikp__IKP__ikgad/IKG10_010.px . Accessed 8 Feb 2019.
GDP, at current prices. Oficialiosios Statistikos Portalas, Statistics Lithuania. https://osp.stat.gov.lt/statistiniu-rodikliu-analize?indicator=S7R183#/ . Accessed 8 Feb 2019.
Linde M, Dahlöf C. Attitudes and burden of disease among self-considered migraineurs—a nation-wide population-based survey in Sweden. Cephalalgia. 2004;24(6):455–65. https://doi.org/10.1111/j.1468-2982.2004.00703.x.
Brown JS, Neumann PJ, Papadopoulos G, et al. Migraine frequency and health utilities: findings from a multisite survey. Value Health. 2008;11:315–21.
Stafford MR, Hareendran A, Ng-Mak DS, Insinga RP, Xu R, Stull DE. EQ-5D-derived utility values for different levels of migraine severity from a UK sample of migraineurs. Health Qual Life Outcomes. 2012;10:65.
Stewart WF, Lipton RB, Kolodner K, Liberman J, Sawyer J. Reliability of the migraine disability assessment score in a population-based sample of headache sufferers. Cephalalgia. 1999;19(2):107–14. discussion 74
Xu R, Insinga RP, Golden W, Hu XH. EuroQol (EQ-5D) health utility scores for patients with migraine. Qual Life Res. 2011;20(4):601–8.
EuroQol. https://euroqol.org/. Accessed 1 Mar 2018.
Headache Impact Test (HIT-6). https://www.optum.com/solutions/life-sciences/answer-research/patient-insights/condition-specific-surveys.html. Accessed 3 May 2018.
Steiner TJ, Jensen R, Katsarava Z, Stovner LJ, Uluduz D, Adarmouch L, Al Jumah M, Al Khathaami AM, Ashina M, Braschinsky M, Broner S, Eliasson JH, Gil-Gouveia R, Gómez-Galván JB, Gudmundsson LS, Herekar AA, Kawatu N, Kissani N, Kulkarni GB, Lebedeva ER, Leonardi M, Linde M, Luvsannorov O, Maiga Y, Milanov I, Mitsikostas DD, Musayev T, Olesen J, Osipova V, Paemeleire K, Peres MFP, Quispe G, Rao GN, Risal A, de la Torre ER, Saylor D, Togha M, Yu SY, Zebenigus M, Zewde YZ, Zidverc-Trajković J, Tinelli M; Lifting The Burden: the Global Campaign against Headache. Structured headache services as the solution to the ill-health burden of headache: 1. Rationale and description. J Headache Pain. 2021;22(1):78.
Biddle AK, Shih Y-CT, Kwong WJ. Cost-benefit analysis of sumatriptan tablets versus usual therapy for treatment of migraine. Pharmacotherapy. 2000;20:1356–64.
Ramsberg J, Henriksson M. The cost-effectiveness of oral triptan therapy in Sweden. Cephalalgia. 2007;27:54–62.
Slof J, Badia X, Magaz S, Láinez MJA, Galván J, Heras J. Cost-efficacy of oral triptans in the treatment of acute migraine. J Med Econ. 2005;8:27–43.
Witt CM, Reinhold T, Jena S, Brinkhaus B, Willich SN. Cost-effectiveness of acupuncture treatment in patients with headache. Cephalalgia. 2008;28:334–45.
National Institute for Health and Care Excellence (2012, updated 2015) Headaches in over 12s: diagnosis and management. Clinical guideline [CG150]. NICE, at: https://www.nice.org.uk/Guidance/CG150. (Surveillance report 2016, https://www.nice.org.uk/guidance/cg150/resources/surveillance-report-2016-headaches-in-over-12s-diagnosis-and-management-2012-nice-guideline-cg150-2721165808/chapter/Surveillance-decision?tab=evidence; Appendix A: Summary of new evidence from surveillance, https://www.nice.org.uk/guidance/cg150/evidence/appendix-a-summary-of-new-evidence-pdf-2721165806).
Ruggeri M, Drago C, Rosiello F, Orlando V, Santori C. Economic evaluation of treatments for migraine: an assessment of the generalizability following a systematic review. PharmacoEconomics. 2020;38:473–84.
International Headache Society Clinical Trials Subcommittee, Tfelt-Hansen P, Pascual J, Ramadan N, Dahlöf C, D’Amico D, Diener H-C, Møller Hansen J, Lanteri-Minet M, Loder E, McCrory D, Plancade S, Schwedt T. Guidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators. Cephalalgia. 2012;32:6–38.
Derry S, Wiffen PJ, Moore RA. Aspirin for acute treatment of episodic tension-type headache in adults. Cochrane Database Syst Rev. 2017;1:CD011888. https://doi.org/10.1002/14651858.CD011888.pub2.
Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012;2:CD008615. https://doi.org/10.1002/14651858.CD008615.pub2.
Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22:633–58.
Steiner TJ. What efficacy measures are clinically relevant and should be used in Cochrane reviews of acute migraine trials? An alternative viewpoint. Cephalalgia. 2015;35:460–2.
Tfelt-Hansen PC. What efficacy measures are clinically relevant and should be used in Cochrane Reviews of acute migraine trials? A comment. Cephalalgia. 2015;35:457–9.
Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1–211.
Landy SH, Runken MC, Bell CF, Higbie RL, Haskins LS. Assessing the impact of migraine onset on work productivity. J Occup Environ Med. 2011;53:74–81.
Raggi A, Grazzi L, Grignani E, Leonardi M, Sansone E, Scaratti C, D'Amico D. The use of MIDAS in patients with chronic migraine and medication-overuse headache: should we trust it? Neurol Sci. 2018;39:S125–7.
D'Amico D, Grazzi L, Curone M, Leonardi M, Raggi A. Cost of medication overuse headache in Italian patients at the time-point of withdrawal: a retrospective study based on real data. Neurol Sci. 2017;38(Suppl 1):3–6.
Raggi A, Leonardi M, Scaratti C, Sansone E, Grazzi L, D'Amico D. Gender and education inequalities in the cost of medication-overuse headache. Neurol Sci. 2018;39:S117–9.
Yu S, He M, Liu R, Feng J, Qiao X, Yang X, Cao X, Zhao G, Fang Y, Steiner TJ. Headache yesterday in China: a new approach to estimating the burden of headache, applied in a general-population survey in China. Cephalalgia. 2013;33(15):1211–7. https://doi.org/10.1177/0333102413490347.
Steiner TJ, Rao GN, Kulkarni GB, Gururaj G, Stovner LJ. Headache yesterday in Karnataka state, India: prevalence, impact and cost. J Headache Pain. 2016;17(1):74. https://doi.org/10.1186/s10194-016-0669-y.
Ayzenberg I, Katsarava Z, Sborowski A, Obermann M, Chernysh M, Osipova V, Tabeeva G, Steiner TJ. Headache yesterday in Russia: its prevalence and impact, and their application in estimating the national burden attributable to headache disorders. J Headache Pain. 2015;16(1):7. https://doi.org/10.1186/1129-2377-16-7.
Tinelli M, Leonardi M, Paemeleire K, Mitsikostas D, de la Torre ER, Steiner TJ; European Brain Council Value of Treatment Headache Working Group, the European Headache Federation, the European Federation of Neurological Associations, and Lifting The Burden: the Global Campaign against Headache. Structured headache services as the solution to the ill-health burden of headache. 2. Modelling effectiveness and cost-effectiveness of implementation in Europe: methodology. J Headache Pain. 2021;22(1):99.
Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barré J, Katsarava Z, Lainez JM, Lampl C, Lantéri-Minet M, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Andrée C. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 2012;19:703–11.
Dent W, Stelzhammer B, Meindl M, Matuja WB, Schmutzhard E, Winkler AS. Migraine attack frequency, duration, and pain intensity: disease burden derived from a community-based survey in northern Tanzania. Headache. 2011;51:1483–92.
Cristofolini A, Dalla Serra P, Scherillo G, Orrico D, Micciolo R. The prevalence of headache in a population of health care workers and the effects on productivity costs. Med Lav. 2008;99:8–15.
Vinding GR, Zeeberg P, Lyngberg A, Nielsen RT, Jensen R. The burden of headache in a patient population from a specialized headache centre. Cephalalgia. 2007;27:263–70.
Unalp A, Dirik E, Kurul S. Prevalence and characteristics of recurrent headaches in Turkish adolescents. Pediatr Neurol. 2006;34:110–5.
Moens G, Johannik K, Verbeek C, Bulterys S. The prevalence and characteristics of migraine among the Belgian working population. Acta Neurol Belg. 2007;107:84–90.
D’Amico D, Genco S, Perini F. Workplace disability in migraine: an Italian experience. Neurol Sci. 2004;25:s251–2.
Schwartz BS, Stewart WF, Lipton RB. Lost workdays and decreased work effectiveness associated with headache in the workplace. J Occup Environ Med. 1997;39:320–7.
Kryst S, Scherl E. A population-based survey of the social and personal impact of headache. Headache. 1994;34:344–50.
Selekler HM, Gökmen G, Alvur TM, Steiner TJ. Productivity losses attributable to headache, and their attempted recovery, in a heavy-manufacturing workforce in Turkey: implications for employers and politicians. J Headache Pain. 2015;16(1):96. https://doi.org/10.1186/s10194-015-0579-4.
Steiner TJ, Jensen R, Katsarava Z, Stovner LJ, Uluduz D, Adarmouch L, Al Jumah M, Al Khathaami AM, Ashina M, Braschinsky M, Broner S, Eliasson JH, Gil-Gouveia R, Gómez-Galván JB, Gudmundsson LS, Herekar AA, Kawatu N, Kissani N, Kulkarni GB, Lebedeva ER, Leonardi M, Linde M, Luvsannorov O, Maiga Y, Milanov I, Mitsikostas DD, Musayev T, Olesen J, Osipova V, Paemeleire K, Peres MFP, Quispe G, Rao GN, Risal A, de la Torre ER, Saylor D, Togha M, Yu SY, Zebenigus M, Zewde YZ, Zidverc-Trajković J, Tinelli M; Lifting The Burden: the Global Campaign against Headache. Structured headache services as the solution to the ill-health burden of headache: 1. Rationale and description. J Headache Pain. 2021;22(1):78.
Wagner B, Riggs P, Mikulich-Gilbertson S. The importance of distribution-choice in modeling substance use data: a comparison of negative binomial, beta binomial, and zero-inflated distributions. Am J Drug Alcohol Abuse. 2015;41(6):489–97.
JBA P, Palmer S, Sapra S, Shah N, Desai P, Villa G, Lipton RB. Modeling migraine day frequency using the beta-binomial distribution: A case study of erenumab as migraine prophylaxis. Presented at ISPOR 22nd Annual International Meeting, Boston, United States; 2017.
Porter JK, Brennan A, Palmer S, Sapra S, Cristino J. Parametric simulation of headache day frequency using a negative binomial distribution: a case study of Erenumab in episodic migraine. Value Health. 2016;19(7):A361.
Lee JH, Han G, Fulp WJ, Giuliano AR. Analysis of overdispersed count data: application to the human papillomavirus infection in men (HIM) study. Epidemiol Infect. 2012;140(6):1087–94.
Quan HM, Mao X, Wang L. A case study of modeling and exposure-response prediction for count data. J Biopharm Stat. 24(5):1073–90.
Houle TT, Turner DP, Houle TA, et al. Rounding behavior in the reporting of headache frequency complicates headache chronification research. Headache. 2013;53(6):908–19.
Silberstein SD, Hulihan J, Karim MR, Wu SC, Jordan D, Karvois D, et al. Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study. Clin Ther. 2006;28(7):1002–11.
Altman DG, Royston P. The cost of dichotomising continuous variables. BMJ. 2006;332(7549):1080.
Ministry of Health, Labour and Welfare. Basic Survey on Wage. Structure. 2017; https://www.mhlw.go.jp/english/database/db-l/ordinary.html. Accessed 1 Oct 2020
World Health Organization. Headache disorders 2016. https://www.who.int/news-room/fact-sheets/detail/headache-disorders. Accessed 1 Oct 2020.
Kotani K, Shimomura T, Ikawa S, Sakane N, Ishimaru Y, Adachi S. Japanese with headache: suffering in silence. Headache. 2004;44(1):108–9.
Chinese Medical Association Group. Guide to the prevention and treatment of migraine in China [Chinese]. Chin J Pain Med. 2016;22:721–7.
Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3–20. https://doi.org/10.1111/head.12499.
Meyers JL, Davis KL, Lenz RA, Sakai F, Xue F. Treatment patterns and characteristics of patients with migraine in Japan: a retrospective analysis of health insurance claims data. Cephalalgia. 2019;39(12):1518–34.
Lanteri-Minet M. Economic burden and costs of chronic migraine. Curr Pain Headache Rep. 2014;18(1):385.
Insinga RP, Ng-Mak DS, Hanson ME. Costs associated with outpatient, emergency room and inpatient care for migraine in the USA. Cephalalgia. 2011;31:1570–5. 2011/10/21. https://doi.org/10.1177/0333102411425960.
Jacob L, Kostev K. Prescription patterns and the cost of migraine treatments in German general and neurological practices. Pain Pract. 2017;17:747–52. 2016/09/14. https://doi.org/10.1111/papr.12520.
Albers L, Kries RV, Straube A, et al. Age- and sex-specific first health care use for migraine in 2016 in children and adolescents from prospectively collected health insurance data in Germany. Cephalalgia. 2019;39:1156–63. 2019/04/13. https://doi.org/10.1177/0333102419844543.
Law EF, Palermo TM, Zhou C, et al. Economic Impact of Headache and Psychiatric Comorbidities on Healthcare Expenditures Among Children in the United States: A Retrospective Cross-Sectional Study. Headache. 2019;59:1504–15. 2019/09/15. https://doi.org/10.1111/head.13639.
Hjalte F, Olofsson S, Persson U, Linde M. Burden and costs of migraine in a Swedish defined patient population–a questionnaire-based study. J Headache Pain. 2019;20(1):65.
European Medicines Agency (EMA). Summary of Product Characteristics. BOTOX® 50 Allergan Units, Powder for Solution for Injection. European Medicines Agency (EMA). 2019.
Chalmer MA, Hansen TF, Lebedeva ER, Dodick DW, Lipton RB, Olesen J. Proposed new diagnostic criteria for chronic migraine. Cephalalgia. 2019:1–8.
Manack AN, Buse DC, Lipton RB. Chronic migraine: epidemiology and disease burden. Curr Pain Headache Rep. 2011;15(1):70–8.
Stovner LJ, Andrée C, Committee ES. Impact of headache in Europe: a review for the Eurolight project. J Headache Pain. 2008;9:139–46. https://doi.org/10.1007/s10194-008-0038-6.
Buse DC, Manack AN, Serrano D, Varon SF, Turkel LRB. Headache impact of chronic and episodic migraine: predictors of impact from the American migraine prevalence and prevention (AMPP) study. Headache. 2012;52(1):3–17.
Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics. 1993;4:353–65.
Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, Lipton RB. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599–609.
Sumelahti M-L, Mattila K, Sumanen M. Painful musculosceletal disorders and depression among working aged migraineurs. Acta Neurol Scand. 2018;138:93–8.
Giorgi G, Arcangeli G, Perminiene M, Lorini C, Ariza-Montes A, Fiz-Perez J, Di Fabio A, Mucci N. Work-related stress in the banking sector: a review of incidence, correlated factors, and major consequences. Front Psychol. 2017;8:2166.
Burton WN, Conti DJ, Chen CY, Schultz AB, Edington DW. The economic burden of lost productivity due to migraine headache: a specific worksite analysis. J Occup Environ Med. 2002;44:523–9.
Nagata T, Mori K, Ohtani M, Nagata M, Kajiki S, Fujino Y, Matsuda S, Loeppke R. Total health-related costs due to absenteeism, presenteeism, and medical and pharmaceutical expenses in Japanese employers. J Occup Environ Med. 2018;60:e273.
Hepp Z, Dodick DW, Varon SF, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 2017;37:470–85. https://doi.org/10.1177/0333102416678382.
Buse DC, Yugrakh MS, Lee LK, et al. Burden of illness among people with migraine and >/= 4 monthly headache days while using acute and/or preventive prescription medications for migraine. J Manag Care Spec Pharm. 2020;26:1334–43. https://doi.org/10.18553/jmcp.2020.20100.
Hines D, Shah S, Multani J, et al. Changes in acute migraine-specific medications after initiating erenumab: results from a real-world retrospective cohort study in the United States (1685). Neurology. 2020;94:1685.
Tepper S, Fang J, Vo P, et al. Impact of erenumab on acute medication usage and healthcare resource utilization among migraine patients: a US claims database study. Cephalalgia. 2020;40:97–9.
Faust E, Pivneva I, Yang K, et al. Reductions in migraine frequency and duration in patients with chronic migraine treated with erenumab: interim results from a real-world multicenter chart-review study of US headache centers MTV20-DP-001. Cephalalgia. 2020;40:18–110.
Freitag FG, Lyss H, Nissan GR. Migraine disability, healthcare utilization, and expenditures following treatment in a tertiary headache center. Bayl Univ Med Cent Proc. 2013;26(4):363–7.
Bonafede M, Cai Q, Cappell K, et al. Factors associated with direct health care costs among patients with migraine. J Manag Care Spec Pharm. 2017;23(11):1169–76.
Miller S. The acute and preventative treatment of episodic migraine. Ann Indian Acad Neurol. 2012;15(Suppl 1):S33–9.
Weatherall MW. The diagnosis and treatment of chronic migraine. Ther Adv Chronic Dis. 2015;6(3):115–23.
Wu J, Hughes MD, Hudson MF, Wagner PJ. Antimigraine medication use and associated health care costs in employed patients. J Headache Pain. 2012;13(2):121–7.
Messali A, Owens G, Bloudek L, Kori S, Cole A, Chia J. Health care resource utilization following initiation of a triptan: a retrospective claims analysis. J Manag Care Spec Pharm. 2014;20(4):368–75.
Etemad LRea. Costs and utilization of triptan users who receive drug prophylaxis for migraine versus triptan users who do not receive drug prophylaxis. J Manag Care Pharm. 2005;11(2):137–44.
Swedish Headache Society. Treatment guidelines migraine. 2017. http://www.huvudvarkssallskapet.se/diagnostik_behandling.php?category_id=3. Accessed Sept 2019.
Goadsby PJ, Paemeleire K, Broessner G, et al. Efficacy and safety of erenumab (A MG334) in episodic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia. 2019;39:817–29.
Ashina M, Tepper S, Brandes JL, Reuter U, et al. Efficacy and safety of erenumab (A MG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia. 2018;38(10):1611–21.
Brown JS, Papadopoulos G, Neumann PJ, Price M, Friedman M, Menzin J. Cost-effectiveness of migraine prevention: the case of topiramate in the UK. Cephalalgia. 2006;26(12):1473–82.
Silberstein SD, Lipton RB, Dodick D, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007;47(2):170–80.
Brandes JL, Saper JR, Diamond M, et al. Topiramate for Migraine prevention. JAMA. 2004;291(8):965–73.
Láinez MJ. The effect of migraine prophylaxis on migraine-related resource use and productivity. CNS Drugs. 2009;23(9):727–38.
Tepper S, Ashina M, Reuter U, Brandes JL, Dolezil D, Silberstein S, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425–34.
Lipton RB, Tepper SJ, Reuter U, Silberstein S, Stewart WF, Nilsen J, Leonardi DK, Desai P, Cheng S, Mikol DD, Lenz R. Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study. Neurology. 2019;92(19):e2250–60.
Vikelis M, Argyriou AA, Dermitzakis EV, Spingos KC, Mitsikostas DD. Onabotulinumtoxin-A treatment in Greek patients with chronic migraine. J Headache Pain. 2016;17(1):84.
Fendrick AM, Smith DG, Chernew ME, Shah SN. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. Am J Manag Care. 2001;7(9):861–74.
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1–211.
Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache. 2015;55(Suppl 2):103–22. (quiz 23–6)
Lafata JE, Moon C, Leotta C, Kolodner K, Poisson L, et al. The medical care utilization and costs associated with migraine headache. J Gen Intern Med. 2004;19:1005–7.
Antonaci F, Dumitrache C, De Cillis I, Allena M. A review of current European treatment guidelines for migraine. J Headache Pain. 2010;11:13–9.
Goldberg LD. The cost of migraine and its treatment. Am J Manag Care. 2005;11:S62–7.
Steiner TJ, Jensen R, Katsarava Z, Linde M, MacGregor EA, Osipova V, Paemeleire K, Olesen J, Peters M, Martelletti P, on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache. Aids to management of headache disorders in primary care (2nd edition). J Headache Pain. 2019;20:57.
Katsarava Z, Steiner TJ. Neglected headache: ignorance, arrogance or insouciance? Cephalalgia. 2012;32:1019–20.
Antonaci F, Valade D, Lanteri-Minet M, Láinez JM, Jensen J, Steiner TJ. Proposals for the organisation of headache services in Europe. Intern Emerg Med. 2008;3:S25–8.
Steiner TJ, Jensen R, Katsarava Z, Uluduz D, Tinelli M, Thomas H, Stovner LJ. The healthcare solution to headache. Ch 15. In: Steiner TJ, Stovner LJ, editors. Societal impact of headache. Burden, costs and response. Cham: Springer Nature; 2019. p. 203–24.
Lifting The Burden. The global campaign against headache. http://www.l-t-b.org. Accessed 6 June 2021.
European Headache Federation. https://ehf-org.org. Accessed 6 June 2021.
Laughey WF, Holmes WF, Mac Gregor AE, Sawyer JPC. Headache consultation and referral patterns in one UK general practice. Cephalalgia. 1999;19:328–9.
Tfelt-Hansen P. Review. Pharmacological strategies to treat attacks of episodic migraine in adults. Expert Opin Pharmacother. 2020;22(3):305–16. https://doi.org/10.1080/14656566.2020.1828347.
World Health Organization. Headache disorders and public health. Education and management implications. Geneva: WHO (WHO/MSD/MBD/00.9); 2000.
World Health Assembly. Synergies in addressing the burden of epilepsy and other neurological disorders. WHA73_5_en WHO 2020; 2020.
World Health Organization and United Nations Children’s Fund (UNICEF) Global Conference on Primary Health Care (2018) Declaration of Astana. From Alma-Ata towards universal health coverage and the sustainable development goals. WHO/UNICEF, Astana.
Lifting The Burden. http://www.l-t-b.org.
Tinelli M, Leonardi M, Paemeleire K, Raggi A, Mitsikostas D, de la Torre ER, Steiner TJ; European Brain Council Value of Treatment Headache Working Group, the European Headache Federation, the European Migraine and Headache Alliance and Lifting The Burden: the Global Campaign against Headache. Structured headache services as the solution to the ill-health burden of headache. 3. Modelling effectiveness and cost-effectiveness of implementation in Europe: findings and conclusions. J Headache Pain. 2021;22(1):90.
Linde M, Steiner TJ, Chisholm D. Cost-effectiveness analysis of interventions for migraine in four low- and middle-income countries. J Headache Pain. 2015;16:15.
Steiner TJ, Linde M, Schnell-Inderst P. A universal outcome measure for headache treatments, care-delivery systems and economic analysis. J Headache Pain. 2021;22:63.
Tinelli M, Leonardi M, Paemeleire K, et al. Structured headache services as the solution to the ill-health burden of headache. 3. Modelling effectiveness and cost-effectiveness of implementation in Europe: findings and conclusions. J Headache Pain. 2021;22:90. https://doi.org/10.1186/s10194-021-01305-8.
Steiner TJ, Jensen R, Katsarava Z, Stovner LJ, Uluduz D, Adarmouch L, Al Jumah M, Al Khathaami AM, Ashina M, Braschinsky M, Broner S, Eliasson JH, Gil-Gouveia R, Gómez-Galván JB, Guðmundsson LS, Herekar AA, Kawatu N, Kissani N, Kulkarni GB, Lebedeva ER, Leonardi M, Linde M, Luvsannorov O, Maiga Y, Milanov I, Mitsikostas DD, Musayev T, Olesen J, Osipova V, Paemeleire K, Peres MFP, Quispe G, Rao GN, Risal A, Ruiz de la Torre E, Saylor D, Togha M, Yu SY, Zebenigus M, Zenebe Zewde Y, Zidverc-Trajković J, Tinelli M, on behalf of Lifting The Burden: the Global Campaign against Headache. Structured headache services as the solution to the ill-health burden of headache. 1. Rationale and description. J Headache Pain. 2021;22:78.
GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459–80. https://doi.org/10.1016/S1474-4422(18)30499-X.
Viana M, Khaliq F, Zecca C, Figuerola MDL, Sances G, Di Piero V, Petolicchio B, Alessiani M, Geppetti P, Lupi C, Benemei S, Iannacchero R, Maggioni F, Jurno ME, Odobescu S, Chiriac E, Marfil A, Brighina F, Barrientos Uribe N, Pérez Lago C, Bordini C, Lucchese F, Maffey V, Nappi G, Sandrini G, Tassorelli C. Poor patient awareness and frequent misdiagnosis of migraine: findings from a large transcontinental cohort. Eur J Neurol. 2020;27(3):536–41. https://doi.org/10.1111/ene.14098.
Tinelli M, Leonardi M, Paemeleire K, Mitsikostas D, de la Torre ER, Steiner TJ, on behalf of the European Brain Council Value of Treatment Headache Working Group, the European Headache Federation, the European Federation of Neurological Associations, and Lifting The Burden: the Global Campaign against Headache. Structured headache services as the solution to the ill-health burden of headache. 2: modelling effectiveness and cost-effectiveness of implementation in Europe: methodology. J Headache Pain. 2021;22:99.
GBD. Viewpoint collaborators (2020) Five insights from the global burden of disease study 2019. Lancet. 2019;396:1135–59.
Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA. 2003;290(18):2443–54. https://doi.org/10.1001/jama.290.18.2443.
Simić S, Rabi-Žikić T, Villar JR, Calvo-Rolle JL, Simić D, Simić SD. Impact of individual headache types on the work and work efficiency of headache sufferers. Int J Environ Res Public Health. 2020;17(18):6918. https://doi.org/10.3390/ijerph17186918.
Kothari SF, Jensen RH, Steiner TJ. The relationship between headache-attributed disability and lost productivity: 1. A review of the literature. J Headache Pain. 2021;22(1):73.
Thomas H, Kothari SF, Husøy A, Jensen RH, Katsarava Z, Tinelli M, Steiner TJ. The relationship between headache-attributed disability and lost productivity: 2. Empirical evidence from population-based studies in nine disparate countries. J Headache Pain. 2021;22(1):153.
Steiner TJ, Jensen R, Katsarava Z, Stovner LJ, Uluduz D, Adarmouch L, Al Jumah M, Al Khathaami AM, Ashina M, Braschinsky M, Broner S, Eliasson JH, Gil-Gouveia R, Gómez-Galván JB, Guðmundsson LS, Kawatu N, Kissani N, Kulkarni GB, Lebedeva ER, Leonardi M, Linde M, Luvsannorov O, Maiga Y, Milanov I, Mitsikostas DD, Musayev T, Olesen J, Osipova V, Paemeleire K, Peres MFP, Quispe G, Rao GN, Risal A, Ruiz de la Torre E, Saylor D, Togha M, Yu SY, Zebenigus M, Zenebe Zewde Y, Zidverc-Trajković J, Tinelli M, on behalf of Lifting The Burden: the Global Campaign against Headache. Structured headache services as the solution to the ill-health burden of headache. 1: rationale and description. J Headache Pain. 2021;22:78.
World Health Organization. Choosing Interventions that are Cost–Effective (WHO-CHOICE). Project WHO | WHO-CHOICE. WHO https://www.who.int/news-room/feature-stories/detail/new-cost-effectiveness-updates-from-who-choice (Accessed 27 July 2021) 2014.
World Health Organization. Universal health coverage 2020. https://www.who.int/health-topics/universal-health-coverage#tab=tab_1 (Accessed 13 Dec 2020).
Schramm S, Uluduz D, Gouveia RG, et al. Headache service quality: evaluation of quality indicators in 14 specialist-care centres. J Headache Pain. 2016;17(1):111.
Braschinsky M, Haldre S, Kals M, Arge M, Saar B, Niibek M, Katsarava Z, Steiner TJ. Structured education to improve primary-care management of headache: how long do the benefits last? A follow-up observational study. Eur J Neurol. 2018;25(3):497–502. https://doi.org/10.1111/ene.13524.
World Health Organization and Lifting The Burden. Atlas of headache disorders and resources in the world 2011. Geneva: World Health Organization; 2011.
Steiner TJ, Jensen R, Katsarava Z, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache. J Headache Pain. 2019;20(1):57.
Yoon MS, Katsarava Z, Obermann M, Fritsche G, Oezyurt M, Kaesewinkel K, Katsarova A, Santowski I, Diener H, Moebus S. Prevalence of primary headaches in Germany: results of the German headache consortium study. J Headache Pain. 2012;13:215–23.
Steiner TJ, Paemeleire K, Jensen R, Valade D, Savi L, Lainez MJA, Diener H-C, Martelletti P, Couturier EGM. European principles of management of common headache disorders in primary care. J Headache Pain. 2007;8(suppl 1):S3–S21.
Hungarian Headache Society. List of headache centers in Hungary http://fejfajas-tarsasag.hu/info.aspx?sp=17.
May A, et al. EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. Eur J Neurol. 2006;13:1066–77.
Cevoli S, D’Amico D, Martelletti P, Valguarnera F, Del Bene E, De Simone R, Sarchielli P, Narbone M, Testa L, Genco S, Bussone G, Cortelli P. Underdiagnosis and undertreatment of migraine in Italy: a survey of patients attending for the first time 10 headache centres. Cephalalgia. 2009;29(12):1285–93. https://doi.org/10.1111/j.1468-2982.2009.01874.x.
Brockmann N, Evers S. Migraine in neurologists and headache specialists. Headache. 2010;50(1):138–40.
Alstadhaug KB, Hernandez A, Næss H, et al. Migraine among Norwegian neurologists. Headache. 2012;52(9):1369–76.
Lu SR, Wang SJ, Fuh JL. The practice pattern of migraine management among neurologists in Taiwan. Cephalalgia. 2006;26(3):310–3.
Yeh WZ, Blizzard L, Taylor BV. What is the actual prevalence of migraine. Brain Behav. 2018;8(6):e00950.
Hettiarachchi J, Lipton RB, Dodick D, et al. A self administered screener for migraine in primary care. Neurology. 2012;61(3):375–82.
Evans RW, Evans RE, Kell HJ. A survey of family doctors on the likeability of migraine and other common diseases and their prevalence of migraine. Cephalalgia. 2010;30(5):620–3.
Waters WE. Migraine in general practitioners. Br J Prev Soc Med. 1975;29:48–52.
Dalsgaard-Nielsen T, Ulrich J. Prevalence and heredity of migraine and migrainoid headaches among 461 Danish doctors. Headache. 1973;12(4):168–72.
Diener H-C, Holle-Lee D, Nägel S, Dresler T, Gaul C, Göbel H, Heinze-Kuhn K, Jürgens T, Kropp P, Meyer B, May A, Schulte L, Solbach K, Straube A, Kamm K, Förderreuther S, Gantenbein A, Petersen J, Sandor P, Lampl C. Treatment of migraine attacks and prevention of migraine: Guidelines by the German Migraine and Headache Society and the German Society of Neurology. Clin Translational Neurosci. 2019;3:1–40.
Viticchi G, Silvestrini M, Falsetti L, Lanciotti C, Cerqua R, Luzzi S, Provinciali L, Bartolini M. Time delay from onset to diagnosis of migraine. Headache. 2011;51(2):232–6. https://doi.org/10.1111/j.1526-4610.2010.01778.x.
Goadsby PJ, Sprenger T. Current practice and future directions in the prevention and acute management of migraine. Lancet Neurol. 2010;9:285–98.
Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia Int J Headache. 2018;38(1):1–1211.
World Health Organization. Atlas of headache disorders and resources in the world 2011. Geneva: WHO; 2011.
Stovner LJ, Andree C. Prevalence of headache in Europe: a review for the Eurolight project. J Headache Pain. 2010;11:289–99.
World Bank. http://www.worldbank.org/en/results . Accessed 6 Feb 2017.
Yu S, Zhang M, Zhou J, Liu R, Wan Q, Li Y. Headache care in China. Headache. 2014;54(4):601–9. https://doi.org/10.1111/head.12330.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Martelletti, P. (2022). Public Health. In: Martelletti, P. (eds) Migraine in Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-97359-9_1
Download citation
DOI: https://doi.org/10.1007/978-3-030-97359-9_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-97358-2
Online ISBN: 978-3-030-97359-9
eBook Packages: MedicineMedicine (R0)